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Abstract 
Oxidative stress is caused by an imbalance between the production and removal 
of reactive oxygen species (ROS). Polyunsaturated fatty acids (PUFA), due to their 
multiple carbon-carbon double bonds, react readily with ROS in a process termed lipid 
peroxidation. Lipid peroxidation generates a number of potentially harmful secondary 
products, including the aldehydes ethanal, propanal, and hexanal. Indeed, raised aldehyde 
levels have been associated with various diseases, including cancer, leading researchers 
to consider them as potential diagnostic markers. However the abundance of their fatty 
acid precursors is dependent on dietary intake. As such, tissue aldehyde content may be 
diet-dependent, reducing their desirability as markers. To investigate this I fed 32 male 
Wistar rats diets containing 90% fat-free rat chow, 9% palm oil (mostly saturated fat), 
and 1% omega-3 fatty acid (EPA, DHA, ALA) for 8 weeks. The different diets resulted 
in changed fatty acid lipid composition in rat brain and liver. Compared to controls, DHA 
and EPA diets decreased liver arachidonic acid levels by 10%, while increasing levels of 
EPA and DHA by 7-11%. A similar effect was seen in brain lipid composition, although 
the changes, while statistically significant, weren’t as pronounced. In brain lipids, feeding 
omega-3 PUFA did not lead to great changes in their concentrations, while DHA was 
found to be maintained at high levels even in the absence of any omega-3 PUFA in the 
diet. However, selected ion flow mass-spectrometry (SIFT-MS) analysis of the rat livers 
and brains suggests that diet does not significantly affect the concentrations of various 
aldehydes (P>0.05), or overall levels of oxidative stress (as measured by TBARS assays) 
in liver or brain (P>0.05). My results suggest that volatile aldehydes may represent a 
useful marker for oxidative stress with potential applications in a variety of common 
disorders. 
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Lay Summary 
 Oxidative stress has been found to be a primary cause of a number of disease 
conditions. This can result in lipid peroxidation that leads to the generation of free 
radicals, which in turn, can cause a chain reaction that leads to the destruction of DNA 
and proteins. The degradation of lipid peroxides produces aldehydes, which are more 
stable than reactive oxygen species. This may make them a more stable and reliable 
biomarker of oxidative stress. However, past studies have found that an increase in the 
omega-3 fatty acid content of the diet can lead to increased propanal concentrations in 
tissue, and conversely that an increase in the omega-6 polyunsaturated fatty acid (PUFA) 
content of the diet can lead to increased tissue hexanal concentrations. My research 
examined the effect of feeding different types of omega-3 PUFA on aldehyde 
concentrations, oxidative stress, and lipid compositions in rat brain and liver. I found that 
although omega-3 PUFA supplementation significantly affected lipid compositions, it did 
not affect lipid peroxidation or tissue aldehyde concentrations. These results may signify 
that tissue aldehyde concentrations are unaffected by diet, and may represent a reliable, 
more stable biomarker for oxidative stress. 
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A) Introduction 
 Oxidative stress is caused by the imbalance between the production and removal 
of reactive oxygen species (ROS), and has been associated with numerous disease 
conditions (Valko et al., 2007) The increased amount of double bonds in polyunsaturated 
fatty acids (PUFA) makes them increasingly susceptible to ROS, and can lead to a chain 
reaction of free radical production that causes lipid peroxidation (Halliwell, 2006). The 
degradation of lipid peroxides can in turn produce secondary metabolites, including 
aldehydes that can have toxic effects to our cells through the generation of DNA and 
protein-adducts. It has been suggested that an increase in total PUFA consumption could 
lead to an increase in lipid peroxidation, with a subsequent increase in tissue aldehyde 
concentrations (Halliwell, 2006).  
 
i) Structure and Classification of Fats and Fatty Acids 
 
 Fatty acids are one of the main building blocks of fats. Fatty acids themselves are 
composed of a carbon chain usually from 4-28 carbons long, bonded to hydrogen atoms, 
with a methyl group at one end, and a carboxylic acid group at the other end. However, 
there are many different types of fatty acids. 
 
Fatty acids are monocarboxylic acids derived from animal or vegetable fat, oils, 
or waxes (Altar, 2006).  Fatty acids can be classified based on their chain length, or by 
the presence of double bonds in their carbon chains. Those with no double bonds are said 
to be fully saturated (saturated fatty acids or SFA). Those with one double bond are 
monounsaturated (MUFA), and those with more than one double bond are known as 
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polyunsaturated fatty acids (PUFA). In this experiment I will be analyzing the effect of 
dietary omega-3 fatty acid supplementation on the fatty acid composition of the livers and 
brains of male Wistar rats. This will include several SFA, MUFA, and PUFA (Table 1).  
 
ii) Polyunsaturated Fatty Acids 
 
Fatty acids are important structural components of phospholipid cell membrane 
tissues. They form protective, semi-permeable barriers around cells and our sub-cellular 
structures that allow the cell can to regulate ion movement into and out of the cell with 
the use of proteins called ion pumps (Figure 1). Most naturally produced fatty acid double 
bonds are in cis-configuration, which creates the kinks in the fatty acid chains (Gunstone 
et al., 1994). The kinks in the chain cause them to pack more loosely together than SFA, 
which form straight chains. This allows PUFA to create more fluid and biologically 
active structures, although their increased number of double bonds may lead to an 
increased risk of oxidative injury. While SFA and MUFA can be synthesized by the body 
de novo, certain PUFA cannot as we lack the necessary desaturase enzymes to create 
double bonds closer to the methyl end than the omega-9 carbon (Gunstone et al., 1994).  
 
For the purpose of my experiment PUFA can be split into two main groups: 
omega-3 PUFA and omega-6 PUFA. The number following the omega indicates the first 
carbon containing a double bond, from the terminal, or omega, methyl end of the fatty 
acid. Both omega-6 and omega-3 fatty acids have an essential 18 carbon type, linoleic 
acid (LA, omega-6) and alpha-linolenic acid (ALA, omega-3). Due to the fact that these 
polyunsaturated fatty acids are necessary for body and brain health, and because they 
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cannot be synthesized by the body de novo and must be obtained through the diet, they 
are classified as ‘essential fatty acids’. Once ingested, the 18-carbon LA and ALA can be 
converted by the body into longer chained PUFA, as I describe below. The fatty acid 
content of various fat sources is given in Table 2.  
 
iii) Omega-6 Polyunsaturated Fatty Acids 
 
 Omega-6 PUFA (also known as n-6 PUFA, with ‘n’ referring to the number of 
carbon atoms in the molecule) play important roles throughout the body, particularly in 
the skin. Omega-6 PUFA in the form of gamma-linolenic acid (GLA) and linoleic acid 
(LA) are found in the plant seed oils of evening primrose, black currant, borage, and 
fungal oils, while arachidonic acid (AA) of the omega-6 series is found in egg yolk, 
meats in general, particularly organ meats, and other animal-based foods (Institute of 
Medicine, 2005). The shortest chained omega-6 PUFA, the 18-carbon linoleic acid, is 
incorporated into skin ceramides, and is essential for maintaining the water permeability 
barrier of the skin (European Food Safety Authority, 2005). A prolonged lack of dietary 
omega-6 PUFA has been shown to increase trans-epidermal water loss, causing rough 
and scaly skin, and may contribute to the development of dermatitis (Institute of 
Medicine, 2005).  Linoleic acid has also been shown to lower LDL and total cholesterol 
levels when taken in place of SFA. However, high levels of omega-6 PUFA have also 
been linked with an increased risk of myocardial infarction and coronary thrombosis 
(Simopoulos et al., 2000). 
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 In 1950, Widmer and Holman found that linoleic acid (18-carbon) was the 
precursor for arachidonic acid, a 20-carbon omega-6 PUFA (Holman, 1998). In 1963, it 
was discovered that arachidonic acid was converted into pro-inflammatory prostaglandins 
by the body. By the start of the 1980’s, more pro-inflammatory agents; thromboxanes, 
prostacyclins, leukotrienes, and hydroxyeicosatetraenoic acids (HETE) were discovered. 
All of these pro-inflammatory agents were classified into a group known as eicosanoids, 
given their name for the fact that they are derived from the 20-carbon arachidonic acid, 
with eicosa- meaning twenty in Greek. 
 
Upon stimulation of a tissue, the formation of the omega-6 eicosanoids from 
arachidonic acid is often associated with an explosive, short-lasting, burst of synthesis 
(Rose and Connolly, 1999). This burst provides active eicosanoids that can activate 
specific receptors briefly before being converted to inactive metabolites by selective 
catabolic enzymes (Lands, 1992). If the rate of synthesis is too slow, there will be 
insufficient amounts of active eicosanoids to occupy receptors, whereas if the rate of 
synthesis is too fast, excess active eicosanoids can have deleterious effects, such as heart 
attacks, strokes, arthritis, lupus, and asthma. Because of these potential harmful effects, it 
appears important to limit the amount of arachidonic acid substrate available for 
transformation into eicosanoids. One way of doing this is to simply limit the intake of 
omega-6 PUFA. However, recently another potential solution has started to receive 
significant attention, the use of omega-3 PUFA. 
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iv) Omega-3 Polyunsaturated Fatty Acids 
 
Omega-3 PUFA (also known as n-3 PUFA) originate in the green leaves of plants, 
as well as plankton and algae. Flaxseed is very high in ALA, while fish, who consume the 
plankton or plants, have relatively high concentrations of the 20 carbon eicosapentaenoic 
acid (EPA) and the 22 carbon docossahexaenoic acid (DHA). Some of these fatty acids 
are then passed on to humans as we consume these foods.  
 
It was believed that a small amount of omega−3 PUFA in the diet (~1% of total 
calories) enabled normal growth, and increasing the amount had little to no additional 
effect on growth (Burr and Burr, 1929). Small amounts of omega-3 PUFA prevented 
impaired growth, and so these fatty acids were designated as essential fatty acids. 
Although omega-3 PUFA have been known as essential to normal growth and health 
since the 1930s, awareness of their health benefits has dramatically increased in the past 
few decades.  
Recognition of the potential benefits of omega-3 PUFA occurred in the 1970s with the 
study of Greenland Inuits. From these studies (Dyerberg et al., 1975), it was observed 
that while the Greenland Inuits consumed a diet high in fat, they displayed virtually no 
cardiovascular disease or coronary atherosclerosis. This was believed to be because the 
meat consumed originated from the sea, and that their dietary fat compositions were 
characterized by their maritime origin. The researchers noticed that although their diets 
were high in fat, the composition of the fats had led to reduced triglyceride levels, heart 
rate, blood pressure and atherosclerosis, as well as a 2/3 decrease in the amount of 
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linoleic acid, and a decrease in the amount of arachidonic acid in the phospholipids 
(Dyerberg et al., 1975). These findings are reinforced by similar findings in Japanese 
populations, in which we see lower rates of atherosclerosis and mortality from heart 
failure than Caucasian populations (Yano et al., 1988). These observations led to more 
studies, which have supported a protective effect of omega-3 PUFA, although it is 
important to distinguish between omega-3 PUFA to determine which fatty acid provides 
us with what health benefit.  
v) Omega-3 Polyunsaturated Fatty Acid Conversions 
Omega-3 PUFA have shown a variety of potential health benefits, but it is 
important to note that there are different variations of omega-3 fatty acids PUFA, and that 
they do not all play the same role, and do not all have the same effect on the body and 
brain. There are three main types of omega-3 PUFA; ALA (18:3, n-3), EPA (20:5, n-3), 
and DHA (22:6, n-3) [the numbers in parentheses refer to – the number of carbon atoms 
in the fatty acid: the number of double bonds, and followed, in the case of PUFA and 
MUFA by the family of the fatty acid). As mentioned earlier, these fatty acids cannot be 
synthesized de novo by the body, and must be taken up through the diet. However, once 
ALA is consumed it can then be converted into EPA and later DHA by the body. Because 
of this it was often thought that it was sufficient enough to consume ALA alone, and that 
it would be converted into sufficient amounts of EPA and DHA by the body. It has since 
been shown that this is not the case. 
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ALA is converted by the body through a series of desaturation and elongation 
events into EPA, which is then converted into DHA, again through desaturation and 
elongation (Figure 2). However, ALA’s conversion rate into EPA and DHA is low. A 
study (Gerster, 1998) using radioisotope labeled ALA showed that with a diet high in 
SFA, the conversion efficiency of ALA was about 6% for EPA, and only 3.8% for DHA. 
He also found that a diet high in omega-6 PUFA reduced the conversion rate by about 40-
50% (Gerster, 1998). Goyens et al. 2006, found that the amount of linoleic acid (omega-
6) in the diet affected the conversion rate of ALA to EPA and DHA, and estimated the 
conversion rate of ALA to EPA to be in the area of 0.2-8%. Because of this data, and that 
of further studies, it can be said that ALA, EPA and DHA are not all present in the same 
amounts when simply ALA is consumed. Further research has shown that these fatty 
acids do not all have the same effect on disease pathology, and need to be studied 
separately.  
  
vi) Omega-3 Polyunsaturated Fatty Acids and Cardiovascular Disease 
 
 In 2000, the U.S. Food and Drug Administration (FDA) announced a qualified 
health claim for dietary supplements containing EPA and DHA omega-3 fatty acids and 
the reduced risk of coronary heart disease (U.S. Food and Drug Administration, 2004).  
In 2004, the FDA gave qualified health claim status to EPA and DHA, stating that 
“supportive but not conclusive research shows that consumption of EPA and DHA 
omega-3 PUFA may reduce the risk of coronary heart disease” (U.S. Food and Drug 
Administration, 2004). Omega-3 PUFA have been known to be essential to normal 
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growth and development of the body and the brain, but as the breadth of research and 
information on omega-3 PUFA continues to grow, new and exciting potential health 
benefits are being demonstrated. 
 
 The primary health benefit of omega-3 PUFA seems to be in reducing cholesterol 
and triglycerides in the blood stream that lead to atherosclerosis and eventually heart 
disease. While ALA has shown beneficial effects in some studies, it has also shown 
opposing effects in other studies (Anderson and Ma, 2009). Meanwhile EPA and DHA 
are now known as potent hypotriacylglycerolaemic agents, due to what is thought to be 
their ability to decrease triglyceride synthesis, and also increase triglyceride clearance 
(Anderson and Ma, 2009) through the regulation of arachidonic acid produced 
eicosanoids, lowering of plasma triglycerides and blood pressure, regulation of ion flux in 
cardiac cells, and regulation of gene expression via the peroxisomal proliferation system 
(PPARs) (Lands, 1992). More importantly, their ability to lower triglyceride levels has 
been demonstrated at intake levels that are achievable through our diet (Harris, 1997). 
This gives us a possible method by which North American populations can lower their 
risk of cardiovascular disease simply by making modifications to their diets.  
 
Gester in Switzerland (Gerster, 1998) found that a diet that included 2-3 portions 
of fatty fish per week, or approximately 1.25 g of EPA + DHA per day, showed a 
beneficial role in the prevention of cardiovascular and inflammatory diseases. By 
modulating inflammation within the arterial wall, omega-3 PUFA alter the cellular and 
the structural composition of advanced atherosclerotic plaques in a manner that could 
reduce the incidence of plaque rupture or ulceration (Harris, 1997). Fish oil has also been 
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shown to decrease blood pressure, and improve blood flow in hyperlipidaemic, 
overweight men (Davidson et al., 2007). While it is now fairly well accepted that small 
amounts of omega-3 PUFA can aid with cardiovascular function, there are also many 
other potential health benefits that are being researched, particularly in brain.  
 
vii) Omega-3 Polyunsaturated Fatty Acids and Brain Health 
 
 In 1984 it was found that omega-3 PUFA were required for proper differentiation 
and function of the brain (Holman, 1998). Today we now know that omega-3 PUFA, 
particularly DHA, are required for proper development of not only the body, but also of 
the brain. The late David Horrobin, a pioneer in fatty acid research, says that omega-3 
PUFA comprise approximately eight percent of the average human brain (Horrobin, 
1987). Another leading essential fatty acid researcher, and the man who gave omega-3 
PUFA their name, Ralph Holman, says that “DHA is structure, EPA is function” in the 
human brain (Holman, 1998). The Canadian Government has also recognized the 
importance of omega-3 PUFA, stating that: “DHA, on omega-3 PUFA, supports the 
normal development of the brain, eyes and nerves” (Fitzpatrick, 2002). 
 
In 2007, a published article studied the effect of omega-3 PUFA on the 
accumulation of beta amyloid and tau proteins in mice brain, proteins that are abnormal, 
and may contribute to the development of memory loss in later years. The study found 
that all the groups that were supplemented with DHA experienced lower accumulation of 
these proteins (National Institute on Aging, 2007). Improvements in poor developmental 
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health with essential fatty acid supplementation have been found, and have linked omega-
3 fatty acid deficiency with a variety of mental disorders (Perica and Delas, 2011). 
 
In 1998, a study done at Harvard University (Stoll et al., 1999) found that subjects 
with bipolar disorder were less likely to show a relapse of symptoms when given omega-
3 PUFA and also showed significantly greater recovery when fed omega-3 PUFA than 
found in the placebo group. Biological marker studies have also shown that omega-3 fatty 
acid deficiencies are often found in people with depressive disorders, and that 
supplementation with omega-3 PUFA have led to therapeutic benefits (U.S. Food and 
Drug Administration, 2006). Another study found that out of 100 patients that had 
attempted suicide, on average most had significantly lower levels of EPA in their blood 
when compared to control subjects (Hibbeln et al., 2009). In 2006, the Omega-3 Fatty 
Acids Subcommittee stated that: “The preponderance of epidemiologic and tissue 
compositional studies supports a protective effect of omega-3 essential fatty acid intake, 
particularly EPA and DHA, in mood disorders (Hibbeln et al., 2009),” after studies 
showed that EPA and DHA had potential benefits in treating and preventing bipolar 
disorder and major depressive disorder. Recent works have also shown an omega-3 
PUFA deficiency in patients with anxiety disorders (Ross, 2009), which could contribute 
to depression. Although we cannot be certain of these benefits until the mechanisms by 
which they act are fully established, we can see that there is strong evidence linking 
omega-3 PUFA supplementation with the treatment of depressive disorders. It is 
important to note that the health benefits of omega-3 PUFA are not solely affected by 
their dietary intake, but can also be significantly affected by competition with other fatty 
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acids. It is this competition however, that is the proposed mechanism by which omega-3 
PUFA exert many of their beneficial effects.  
 
viii) Competition between Polyunsaturated Fatty Acids 
  
 One possible explanation for the beneficial effects of omega-3 PUFA 
consumption, particularly in cardiovascular health, may be their ability to compete with 
omega-6 PUFA for transformation into secondary metabolites. In 1963, Holman and 
Mohrhauer (Holman, 1998) found that omega-6 and omega-3 PUFA competed for the 
same enzymatic sites involved in the metabolism of the essential fatty acids, and that they 
could strongly suppress omega-6 metabolism with less than 2% caloric intake coming 
from ALA. The reason for the beneficial effects of this competition appears to be due to 
the fact that both omega-6 and omega-3 PUFA are converted into eicosanoids by the 
body, and that these eicosanoids have opposing effects. While those from omega-6 PUFA 
are known to be pro-inflammatory, those from omega-3 PUFA are said to be anti-
inflammatory.  
 
This competition between omega-6 and omega-3 PUFA was first noticed when it 
was found that the 2-series thromboxanes produced by omega-6 PUFA were an important 
part of the clumping of platelets during thrombosis (Lands, 2005). This discovery 
presented a potential mechanism for slowing thrombosis by simply interfering with 
omega-6 production of thromboxane A2. It was later found that omega-3 PUFA 
supplementation, as well as the use of Asprin, decreased omega-6 PUFA conversion into 
thromboxanes (Lands, 2005). It was also found that omega-3 PUFA supplementation 
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could interfere or slow the production of other omega-6 eicosanoids such as leukotrienes 
and prostaglandins (Lands, 2005). In 1989, a study concluded from their results that 
dietary fish oil may have greater triglyceride lowering effects in individuals eating diets 
high in saturated fats compared with those consuming mainly omega-6 PUFA (Garg et 
al., 1990), showing that not only can omega-3 supplementation decrease omega-6 PUFA 
produced effects, but that the relationship is reciprocal, and that omega-6 PUFA 
supplementation can also decrease the effects produced by omega-3 PUFA. It has become 
increasingly clearer that these two PUFA compete with each other by means of an 
increasingly well understood mechanism. 
 
Recognition that the rate of biosynthesis of prostaglandins was much slower with 
omega-3 derived eicosanoids than with their omega-6 counterparts led immediately to the 
recognition that omega-3 PUFA competitively attenuate the rate of omega-6 eicosanoid 
formation (Lands, 1992). The 20-carbon EPA (omega-3) and AA (omega-6) have been 
found to be converted into different types of prostaglandins (Figure 3). Arachidonic acid 
is converted into 2-series prostaglandins, while EPA is converted into 3-series 
prostaglandins (Lands, 1992). Omega-6 PUFA are converted into prostaglandins and 
thromboxanes by cyclooxygenase (COX)-derived metabolites, while lipoxygenase 
(LOX)-derived metabolites convert them into leukotrienes and HETE eicosanoids 
(Lands, 1992; Anderson and Ma, 2009). Not only does the omega-6 PUFA, arachidonic 
acid, use these pathways, but the omega-3 PUFA, EPA, also uses the same enzymes to be 
transformed (Bell et al., 1997), and the rate of eicosanoid production for each is directly 
affected by the amounts of each precursor fatty acid present in the diet. It is now 
commonly felt that the ratio of omega-3 to omega-6 PUFA is directly responsible for the 
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amount of each type of eicosanoids produced through these COX and LOX pathways 
(Lands, 1992). In the past 100 years we have seen a great shift in dietary omega-6 to 
omega-3 fatty acid ratios in Western populations, a shift that can lead to harmful effects.  
 
ix) Omega-6/Omega-3 Polyunsaturated Fatty Acid Ratio 
 
 A result of the nonselective metabolism of AA and EPA is that the relative 
availability of each in the diet strongly influences the proportions of the types of PUFA 
that are accumulated in tissue lipids. The resultant proportions influence, in turn, the 
proportions of eicosanoid precursor that can be mobilized by tissues upon stimulation, 
and thereby the intensity of the omega-6 eicosanoid response (Lands, 1992). The typical 
Western diet has omega-6: omega-3 PUFA ratios in the area of 10:1 to 40:1. However, 
these are not the ideal ratios one should strive for. Studies suggest that the evolutionary 
human diet, which focused around game animals, seafood, and other marine sources that 
were rich in omega-3 PUFA has led to a need for a balanced ratio between omega-6 and 
omega-3 PUFA (Simopoulos et al., 2000). Typically one should try and achieve a 1:1 to 
4:1 ratio of omega-6 to omega-3 PUFA in order to maximize the health benefits that both 
can provide (Simopoulos et al., 2000).  
  
 PUFA appear to provide numerous health benefits when taken in place of SFA, 
however as with most potential treatments, we must take into consideration that there 
may be some negative side effects. As mentioned, the increased number of double bonds 
in these PUFA may present a potential health risk in high doses, through lipid 
peroxidation and free radical damage. 
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x) Omega-3 Polyunsaturated Fatty Acids and Lipid Peroxidation 
 
An increased degree of desaturation will lead to an increase in lipid peroxidation 
(Sevanian and Hochstein, 1985), which should lead to an increase in lipid peroxidation in 
rats fed EPA over ALA, with an even further increase in those fed DHA over EPA as 
their omega-3 PUFA source. 
 
 Lipid peroxidation is a degradative process which is the consequence of the 
production and propagation of free radicals, primarily involving membrane PUFA, and 
has been associated with numerous diseases (Mutia and Uchida, 1999). Lipid 
peroxidation occurs when reactive oxygen species (ROS) attack fatty acids and initiate 
the production of a fatty acid radical, which combines with water to make a lipid radical. 
This radical is not very stable, and reacts readily with molecular oxygen, creating a 
peroxyl-fatty acid radical. This too is unstable, and reacts with another free fatty acid, 
producing a different fatty acid radical and a lipid peroxide. This cycle continues, as the 
new fatty acid radical reacts in the same way. When a radical reacts with a non-radical, it 
always produces another radical, which is why the process is called a "chain reaction 
mechanism." The radical reaction stops when two radicals react and produce a non-
radical species. This happens only when the concentration of radical species is high 
enough for there to be a high probability of collision of two radicals (Mylonas and 
Kouretas, 1999). But it all stems from the production of reactive oxygen species by the 
body. 
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 Reactive oxygen species are generated during oxidative metabolism, where 
biochemical energy is converted into ATP. In about 0.1–2% of electrons passing through 
the chain, oxygen is prematurely and incompletely reduced to give the superoxide radical 
(·O2
-). Superoxide is in itself highly reactive, but nevertheless, can inactivate specific 
enzymes or can initiate the process of lipid peroxidation (Hill and Batnagar, 1999). 
Superoxide can also leak out of the mitochondria where it is converted into hydrogen 
peroxide (H2O2), which is a major contributor to oxidative damage (Muller, 2000). ROS 
are also generated in response to pathogens, as a defense mechanism (Hill and Batnagar, 
2009). Due to the damaging effects of ROS, the body has evolved a variety of ways to 
protect itself against these ROS.  
 
This protection is done through enzymatic and non-enzymatic antioxidants (Hill 
and Batnagar, 2009). These antioxidants include vitamins C and E in sufficient amounts 
in the diet, among other things, and are the most attractive targets for ROS. If ROS are 
not removed they can react with proteins, DNA, and lipids, as mentioned above. These 
reactions, leading to lipid peroxidation, have long been considered to be involved in the 
initiation, progression, and metastasis of cancer (Pizzimenti et al., 2010), and appear to 
be increased in situations of high dietary omega-3 PUFA consumption. 
 
In 2011, a study (Tsuduki et al., 2011) showed that plasma thiobarbaturic acid 
reactive substances (TBARS) and liver TBARS were approximately doubled when fish 
oil was given to rats.  TBARS assays provide a simple, reproducible and standardized 
way of measuring lipid peroxidation in tissue homogenates, in that thiobarbaturic acid 
reacts with a secondary product of lipid peroxidation, malondialdehyde, to form a 
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coloured product (Cayman Chemical Company 2011). They (Tsuduki et al., 2011) also 
found that mice given long-term fish oil developed severe oxidative stress and had a 
shortened lifespan, and found that the mitochondrial and peroxisomal fatty acid oxidation 
rate was more than doubled with perilla oil (ALA) supplementation, while fish oil more 
than tripled the oxidation rates. This study confirmed an earlier study that also found 
increased fatty acid oxidation in rats fed diets high in omega-3 fatty acids (Wong et al., 
1984). It remains to be determined at just exactly what level of omega-3 PUFA 
consumption do these increased oxidation rates lead to harmful effects on the body, and 
my experiment will try to determine if ALA, EPA, and DHA have different effects. 
Although we are not yet sure if it is harmful, it does appear that omega-3 PUFA 
supplementation increases oxidation rates in various parts of the body, possibly through 
the increased generation of lipid peroxidation- derived aldehydes, and that this needs to 
be taken into consideration when performing tests that use oxidation rates as a biomarker 
of a particular disease. 
 
Although ROS have been shown to have damaging effects in the body, they are 
short-lived due to their high reactivity, which should limit their harmful effects to the site 
of origin (Thannickal and Fanburg, 2000). The fact that ROS are short-lived in the body, 
but that they are still able to cause significant harm throughout the body, may indicate 
that the ROS generate secondary products that can spread injury and amplify damage 
(Thannickal and Fanburg, 2000). PUFA are the most common target of ROS, and when 
oxidized, they generate a variety of bioactive molecules, of which aldehydes are amongst 
the most abundant and reactive (Hill and Batnagar, 2009).  
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xi) Lipid Peroxidation and Aldehydes 
 
There is increasing evidence that endogenous aldehydes generated from lipid 
peroxidation are causally involved in most of the pathophysiological states associated 
with oxidative stress in cells and tissues (Srivastava et al., 2002). When compared with 
free radicals themselves, lipid-derived aldehydes are much more stable and can diffuse 
within, or even escape from the cell and attack targets far from the original free radical-
initiated site (Mutia and Uchida, 1999). Not only are the aldehydes able to diffuse to 
distant sites, but they also possess a rich variety of structural features (either naturally, or 
acquired by conjugation with receptive nucleophiles) that allow them to be recognized by 
cell constituents as signalling molecules (Hill and Batnagar, 2009). These features may 
make them an important secondary metabolite of ROS by which oxidative injury can be 
spread throughout the body.     
 
Two aldehydes of great interest relating to lipid peroxidation are malondialdehyde 
(as measured in the TBARS assay) (MDA) and 4-hydroxy-trans-2-nonenal (4-HNE). 
MDA [CH2(CHO)2] occurs naturally, produced from the degradation of PUFA by 
reactive oxygen species (Figure 4), and is very reactive (Pryor and Stanley, 1975). This 
reactive ability allows MDA to form covalent protein and DNA adducts through reactions 
with deoxyadenosine and deoxyguanosine in DNA (Marnett, 1999). These DNA-adducts 
are toxic to cells, and commonly referred to as advanced lipoxidation end-products 
(Farmer and Davoine, 2007). Because of this, the production of MDA is often used as a 
biomarker to measure the level of oxidative stress in an organism (Del Rio et al., 2005). 
4-HNE is an unsaturated aldehyde that is also produced by lipid peroxidation in cells 
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(Figure 4). 4-HNE, like MDA, has also been found to be increased in oils high in PUFA 
composition, and has been linked with numerous diseases, such as chronic inflammation, 
diabetes, and cancer (Zarkovic, 2003). The increased consumption of PUFA has been 
proposed to increase the production of these aldehydes, which may lead to disease and 
cell death (Surh et al., 2007).  
 There is increasing evidence that endogenous aldehydes generated from lipid  
peroxidation are causally involved in most of the pathophysiological states associated 
with oxidative stress in cells and tissues (Hill et al., 2008).  As early as 1985 studies in 
Chile had found that rats fed a diet high in fish meal and hence, PUFA, showed raised 
blood acetaldehyde levels (Quintanilla, 1993). A connection between high dietary omega-
6 PUFA levels and increased hexanal levels has been proposed (Jarr et al., 1999), while a 
similar correlation has been suggested between omega-3 PUFA and propanal levels 
(Shen, et al., 2007).  The reason for these connections are that a lipid hydroperoxide 
formed at the site of double bonds in omega-3 PUFA should lead to a cleavage between 
the third and fourth carbons (site of first double bond) which will generate water, and the 
3-carbon aldehyde, propanal (Shen et al., 2007). The same theory applies to omega-6 
PUFA, with cleavage generating water and the 6-carbon aldehyde, hexanal (Jarr et al., 
1999). It is possible that a diet high in omega-3 PUFA could be linked to raised 
acetaldehyde and propanal concentrations, while decreasing hexanal concentrations in 
tissue.  
Propanal and hexanal are volatile aldehydes (MDA and HNE are not) which may 
make them useful biomarkers of lipid peroxidation that can be detected in breath or by 
other non-invasive means. The ability to detect propanal and hexanal non-invasively may 
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have great applications in the battle against cancer, diabetes, and other diseases. However 
since these aldehydes are derived from specific fatty acid types, diet could potentially 
change their concentrations, making them unreliable biomarkers. I studied this potential 
link using a novel machine, the Selected Ion Flow Tube- Mass Spectrometer (SIFT-MS) 
to analyze the headspace aldehyde concentrations in rat brain and liver, as outlined in the 
methods section. 
xii) Aldehyde Metabolism 
 
There are enzymes capable of detoxifying these aldehydes, specifically 
glutathione-S-transferases, aldose reductase, and aldehyde dehydrogenase (Chen et al., 
2008). Aldehydes can have toxic effects in the body if not metabolized and removed in an 
orderly fashion. Part of this toxicity is due to their ability to bond nucleic acids and 
proteins and form various DNA and protein-adducts, due to their electrophilic nature (for 
example see O’Brien et al., 2006). Past studies have shown that aldehydes are oxidized to 
carboxylic acids, reduced to alcohols, or conjugated with cellular nucleophiles such as 
proteins (O’Brien et al., 2006). This is done metabolically, and in general aldehydes are 
oxidized by NAD+, and aldehyde dehydrogenase (ALDH) to form carboxylic acids and 
secondary alcohols (O’Brien et al., 2006). In cardiovascular tissue, aldehyde reduction to 
primary alcohols is catalyzed by aldose reductase (AR) (Hill and Batnagar, 2009), but 
they can also be reduced a variety of ways including by alcohol dehydrogenase. 
Aldehydes generated from oxidized lipids have been found in tissues that have 
experienced oxidative injury throughout the body, including in ischemic, hypertrophic, 
and failing hearts; in artherosclerotic lesions, apoptotic cells, and even damaged 
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mitochondria (Hill and Bhatnagar, 2009), and may provide a volatile biomarker for 
cancer.  
 
xiii) Aldehydes and Cancer 
 
 Recent research is now suggesting a possible link between raised aldehyde levels 
in the body and an increased risk of cancer. It is commonly known that increasing ethanol 
consumption may lead to deleterious effects on the body, one of which is an increased 
risk of developing cancer. The principle metabolite of ethanol is the small chain 
aldehyde, acetaldehyde. It has been suggested that acetaldehyde is responsible for the 
increased risk of cancer associated with high concentrations of ethanol consumption. 
However, the body does have ways of detoxifying and removing excess aldehydes, to try 
and protect itself from the danger these aldehydes appear to present.  
 
xiv) Dietary Influence on Tissue Aldehyde Concentrations 
 
 This link between a raised aldehyde level and an increased risk of cancer has led 
to some suggestions that this can be used as a biomarker for cancer. However, although 
high acetaldehyde levels have been linked with an increased risk of cancer in the lab, 
there is still information pointing to the contrary. A study done on the levels of aldehyde 
dehydrogenase 1 (ALDH1) found that raised levels were correlated with a poor 
prognosis, and shorter disease free and survival times (Deng et al., 2010). However, they 
also found that the pattern and level of ALDH1 varied depending on the area of tissue 
examined, and that different body parts had significantly different background levels. 
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This led them to conclude that, although ALDH1 may be promising as a cancer stem cell 
biomarker, that it may not be suitable for use in tissues with high background ALDH1 
levels, such as the liver and pancreas (Deng et al., 2010).  If we can see variations in 
ALDH1 levels within the same individual, then we have to ask whether or not we see 
variations between individuals, and if so, what might be causing this variation?  
 
I used a novel instrument known as a selected ion flow tube- mass spectrometer 
(SIFT-MS), which provides real-time quantification of several trace gases in breath or air, 
or for our purpose, in the headspace of a beaker (Smith & Spanel, 2005, 1999).  
 
The SIFT-MS (Figure 5) generates positive precursor ions using an ion source. 
From the mixture of ion species generated, a current of ions of a given mass-to-charge 
ratio is obtained using a quadrupole mass filter (Smith & Spanel, 2005, 1999). One can 
then select one of three precursor ions (H3O
+, NO+, or O2
+), which react with trace gas 
molecules from the air/breath/headspace introduced through a downstream sampler line. 
No sample work-up is required as the chemical ionization agents are unreactive with the 
major components of air. The sample is simply a small amount of air leaked directly into 
the flow tube. The ions, both product ions and unreacted reagent ions, are carried along 
the flow tube in a stream of helium gas and exit the reaction region through a small 
orifice at the far end. The flow tube pressure is maintained at approximately Torr and the 
reaction time between the ionization agents and the analytes is around 1ms. After 
traversing through the orifice, the ions are focused by a lens array into a second 
quadrupole mass filter located at the downstream end of the instrument where they are 
identified by mass and counted by an ion multiplier. The concentrations of the trace 
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species of interest are found by measuring the ratios of the product ion signals to the 
reagent ion signals providing the relevant kinetic parameters are known. Based on this 
mass-to-charge ratio, and the knowledge of the previously calculated reaction rate 
coefficient, one can deduce the type and concentration of gaseous compounds. 
 
Detection limits are usually in the parts per billion range (ppb), although parts per 
trillion sensitivity (ppt) have been reported (Smith and Spanel, 1999). The SIFT-MS 
machine, unlike the gas chromatography-mass spectrometry does not require water to be 
removed by an equation after each test, in fact it can help in the determination of certain 
chemicals. This reduces the time of each test, and makes breath or headspace 
quantification of volatile chemicals much easier. However, one problem with this 
machine is that we run the risk of mistaking the product produced by the combination of 
a compound with a precursor ion for another one with the same mass-to-charge ratio. To 
date, no one has detected any products that mimic the product ion produced by the 
reaction of NO+ with propanal or hexanal, apart from the 18O isotopologue of hydrated 
hydronium, which has the same m/z as propanal, at m/z 57 (Smith and Spanel, 1999). 
This overlap should be limited in my experiment, which should ensure that this is not a 
problem. 
 
The purpose of my study was to determine whether changes in dietary fatty acid 
intake, which lead to changes in membrane fatty acids concentrations, will alter the 
overall amounts of aldehydes present through changes in overall oxidative stress. I also 
wanted to observe how the relative amounts of propanal and hexanal concentrations vary 
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as the relative omega-3 and -6 PUFA concentrations change. If the volatile aldehydes are 
greatly affected by total omega-3/omega-6 PUFA concentrations, then these markers will 
have large dietary influences, which may make them unsuitable as diagnostic biomarkers. 
Past studies have shown that this may be the case, however these studies used crude oils 
(combination flax/fish oils, containing omega-6 PUFA, SFA, and MUFA as well). We 
now have access to cheaper, highly purified omega-3 PUFA, which allow us to 
investigate the individual effects of each omega-3 PUFA.  
xv) New Purified Omega-3 Polyunsaturated Fatty Acids 
Recently highly purified, vacuum-distilled versions of omega-3 PUFA have 
become available. These new, 95% pure versions of omega-3 PUFA (EPA, DHA, ALA), 
now allow us to isolate specific omega-3 PUFA and use them individually at high levels 
of purity, instead of simply using flax or fish oil. These fatty acids are prepared using a 2-
step process known as cold fractionation. This process takes advantage of the higher 
freezing point of SFA and MUFA, to solidify them, leaving oil containing only PUFA. 
These PUFA are then separated using high performance-liquid chromatography based on 
their size and structural features.  
Studies have already shown a benefit of the purified PUFA against cardiovascular 
disease and diabetes (Horrobin, 2001; Yokohama et al.; 2007, Westerveld et al., 1993), 
and have also shown anti-psychotic and anti-depressive effects (Wood et al.; 2007, Maes 
et al., 1996). With the aid of these purified omega-3 PUFA, I hope to fill in the gaps left 
by previous research, and hope to identify the relationships between omega-3 PUFA, 
lipid peroxidation, and tissue aldehyde concentrations, and to determine whether or not 
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volatile aldehydes present us with a potential biomarker for cancer which is unaffected by 
dietary composition.  
xvi) Hypotheses 
Using the highly purified omega-3 PUFA, I hope to clarify the differences 
between them. I hypothesize that diets supplemented with omega-3 PUFA will show 
increased concentrations of omega-3 PUFA in their tissue phospholipids, while showing 
a decrease in omega-6 PUFA concentrations. Specifically, I hypothesize that EPA and 
DHA supplementation will lead to a greater increase in longer-chained omega-3 PUFA, 
and decrease omega-6 AA concentrations, than ALA supplementation, when compared to 
the palm oil CTRL group. ALA supplementation should lead to increased ALA 
concentrations, with a smaller increase in EPA and DHA concentrations, while EPA 
supplementation should lead to an increase in EPA and DHA concentrations. DHA 
supplementation should only increase DHA concentrations, as the omega-3 PUFA 
conversion pathway (Figure 2) only creates longer-chained PUFA from smaller-chained 
ones.  
I hypothesize that the different omega-3 PUFA will have differential effects on 
lipid peroxidation in rat brains and livers fed diets containing different omega-3 PUFA as 
their principle fat source, due mainly to their different degrees of unsaturation. I also 
hypothesize that I will see differences in the liver and brain headspace aldehyde 
concentrations of the same rats. Specifically, I hypothesize that rats fed diets containing 
EPA and DHA will show higher levels of lipid peroxidation in their livers and brains as 
compared to those fed on either a diet containing ALA as the principal fat source or palm 
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oil control groups, due to their increased number of double bonds. Here I propose that a 
rat with access to a diet high in omega-3 PUFA may show raised acetaldehyde and 
propanal concentrations (through a cleavage at the double bond between the 3rd and 4th 
carbons) in their livers and brains as compared to palm oil control groups. Conversely, I 
expect that diets showing high omega-6 lipid concentrations will give higher headspace 
hexanal concentrations, caused by a cleavage at the double bond between the 6th and 7th 
carbons. These dietary influences on lipid peroxidation, and subsequently tissue aldehyde 
concentrations, should render the analyzed volatile aldehydes unreliable biomarkers of 
oxidative stress and cancer. 
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B) Materials and Methods 
 
i) Rat Storage and Handling 
 
Male Wistar rats were randomly assignedinto pairs and placed into cages 
containing access to water and fat-free rat chow and kept in the the Thunder Bay 
Regional Research Institute, Thunder Bay, Ontario. During this period rats were handled 
periodically to familiarize them with human contact. Cages were cleaned once a weekand 
experiments were carried out ethically under the Lakehead University animal utlilization 
protocol (Lakehead University, 2012). 
 
ii) Fatty Acid Administration 
 
Rats were fed for 8 weeks on supplementation diets containing 90% rat chow 
(containing protein, nutrients, and everything else in a balanced diet apart from fat) and 
10% fat. Control groups were also given palm oil (50% SFA [palmitic acid], 40% MUFA 
[oleic acid], 10% omega-6 PUFA [linoleic acid], and 0.3% ALA) as their fat source (to 
try and replicate the typical Western human diet), while other groups were given 90% 
palm oil and 10% of a specific omega-3 PUFA as their fat source. After food preparation, 
omega-3 PUFA containing canisters were fogged with nitrogen gas to prevent oxidation, 
and stored at -20ºC. Each serving of food contained 315g basal rat mix + 31.5g palm oil + 
3.5g omega-3 fatty acid (315g basal rat mix + 35g palm oil for control group), and rats 
were given unlimited access to food.  
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iii) Euthanizing Procedure  
 
After 8 weeks on the experimental diets, the rats were euthanized by placing them 
in a glass box under a fume hood, and adding a mixture of isofluorane gas and oxygen 
into the gas box to anaesthetize the animals. Rats were then removed from the box and 
decapitated using a small animal guillotine. The livers, brains, and plasma of the rats 
were harvested and stored in a -80°C freezer.  
 
iv) Headspace Aldehyde Analysis 
 
As mentioned, I used a SIFT-MS instrument to analyze tissue headspace aldehyde 
concentrations. This instrument uses the reactions of precursor ions with headspace 
concentrations to produce product ions that can be identified based on their mass-to-
charge ratio (Smith and Spanel, 1999). Before tissue headspace concentrations could be 
analyzed, preliminary work had to be performed.  
 
v) Tissue Preparation and Preliminary Work 
 
The SIFT-MS was used in my experiment to measure the headspace 
concentrations of the saturated, one to eight carbon (C1-C8) aldehydes in the brains and 
livers of our test rats to investigate the effect of dietary omega-3 PUFA supplementation. 
Each aldehyde in the headspace over the tissue will react with the selected precursor ions 
(either H3O
+ or NO+) to produce characteristic product ions that can be identified from 
their mass to charge ratio. The H3O
+ precursor ion was used for formaldehyde and 
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acetaldehyde, as only the protonated parent ion is produced in this reaction, whereas 
when reacted with NO+, we get no reaction occurring, due to the lack of exothermic 
channels, and charge transfer (Smith and Spanel, 1999). All the other aldehydes were 
analyzed using the NO+ precursor ion, which proceeds via hydride (H-) transfer to 
produce a protonated product and HNO in saturated aldehydes. (Smith and Spanel, 1999). 
Typical ion counts varied for each particular aldehyde, but in general I was looking for 
concentrations in the parts per billion range. However, before I could start using 
experimental organs, I first had to run preliminary tests to set the experimental 
parameters.  
 
Firstly, the effect of beaker size on aldehyde measurements was determined. At 
first we were using 250 ml beakers, but after comparison with 125 ml beakers, it was 
determined that the smaller beakers gave more consistent results, and required less tissue 
to produce results in the range we wanted (ideal range was different for each aldehyde, 
but always in ppb).  
 
Before determining how much brain and liver were required to give aldehyde 
concentrations in the optimal range, I first had to determine that range using propanal and 
hexanal standard curves. Hexanal or propanal were mixed with deionized water at various 
dilutions to give readings in the 100-1000 ppb range. Propanal and hexanal quality 
controls (QCs) were used as indicators of the consistency and performance of the SIFT-
MS, and were prepared daily, as their headspace concentrations decrease over time due to 
the volatile nature of the aldehydes (Yasuhara and Shibamoto, 1995). A range of 
headspace aldehyde concentrations was created by creating 4 separate QCs (in triplicates) 
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for each propanal and hexanal, and taking headspace readings of each. From this I 
determined a suitable range for the QCs, with each required to fall within 2 standard 
deviations of the calculated mean (range of 400-800 ppb for propanal, and 100-300 ppb 
for hexanal).     
 
The amount of brain required to give a reliable aldehyde measurement was 
determined. Livers and brains were ground individually and separately in a mortar and 
pestle with the use of liquid nitrogen and separated 125 ml beakers. Using weights of 50 
mg, 100 mg, 150 mg, 300 mg, 500 mg, and 750 mg, headspace aldehyde concentrations 
were recorded at room temperature (22°C), 40°C, and 60°C to check for any effect of 
increasing oxidation at higher temperatures on headspace aldehyde concentrations, and 
also to account for the varying volatility of the aldehydes under consideration. Each 
experiment was repeated twice, with triplicate samples, arriving at an optimal weight of 
200 mg.  
 
The optimal duration of each reading was set by running various spectra of 
different time lengths, checking for dramatic increases or decreases in aldehyde 
concentrations with respect to time. It was determined that 60 seconds was an appropriate 
scan time to allow for accurate and stable results, while keeping the time of each test to a 
minimum.  
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vi) Experimental Procedure 
 
After allowing the machine to warm up for 45-60 minutes, the water level of my 
breath was analyzed by removing the sampler from the sampling line, and breathing into 
the sampling line. Using the H3O
+ precursor ion, the percent of water in breath was 
recorded, and used as a quality control for the SIFT-MS machine, with correct breath 
water vapour concentrations being approximately 6%. Precursor ion purities were 
recorded by turning off the sampling line and using the ‘cycle precursors’ function in 
scan mode. Machine blank concentrations were recorded for each aldehyde by using the 
scan mode on the SIFT-MS and the ‘select compounds’ function to select for aldehydes 
of choice, then running spectra with the sampling line off. These were then subtracted 
from aldehyde concentrations taken from the headspace of the experimental brains and 
livers, recorded with the use of the sampling line. Aldehyde concentrations were recorded 
for a minute for each aldehyde and an average concentration calculated. Quantifiable 
aldehyde concentrations were considered approximately three times higher than machine 
blank concentrations (the recorded concentration of aldehydes with no gas sampling 
occurring due to spectrometer noise and/or carry over contaminants). 
 
Aldehyde concentrations, as mentioned, were first recorded at machine blank 
concentrations, with a source pressure of 0.60 Torr, a tube pressure of 1.012 Torr, a tube 
length of 3 cm and a gas temperature of 25.1˚C, and a microwave power of 92%. The 
direct sample flow rate was 0.43 TorrL/s. After that they were recorded at ambient 
concentrations by placing the sampling line in an empty 125 ml beaker. Finally, 
experimental aldehyde concentrations were recorded by placing the sampling line in the 
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headspace of a 125 ml beaker containing an experimental rat brain or liver. All 
experimental livers and brains ground in liquid nitrogen, weighed, and then immediately 
placed in a 125 ml beaker on dry ice, to prevent any oxidation from taking place. Each 
liver and brain was analyzed in triplicate to reduce experimental error. Once all beakers 
were prepared the first beaker (ambient) was removed from the dry ice and placed at 
room temperature for 5 minutes. Aldehyde concentrations were recorded after 5 minutes 
using the SIFT-MS. After sampling the beaker was resealed using aluminum foil and 
tape, and left at room temperature. While spectra were being run for the first beaker, the 
second beaker was placed at room temperature for 5 minutes. The second beaker was 
then sampled in the same manner as the first beaker, while the third beaker was placed at 
room temperature for 5 minutes. This procedure was followed until all the beakers had 
been sampled at room temperature.  
 
After sampling all beakers at room temperature, machine blank levels were re-
recorded in the same manner as before. While that was being done the first beaker 
(ambient) was placed in a 40°C water bath for 5 minutes to induce oxidation. After 5 
minutes aldehyde levels were recorded using the SIFT-MS, and the beaker was re-sealed 
and left at room temperature as done earlier. The same procedure was the followed for all 
other beakers, using the 40˚C water bath and the SIFT-MS. Machine blanks were then re-
recorded and the same process was repeated at 60˚C.  
 
 
 
 
 32 
 
vii) Lipid Peroxidation Analysis 
 
I measured oxidative stress using a thiobarbaturic acid reactive substances 
(TBARS) assay kit from Cayman Chemical Company. This assay uses thiobarbituric acid 
(TBA), along with diluted acetic acid and diluted sodium hydroxide to prepare a colour 
reagent that is then mixed with sodium dodecyl sulfate (SDS) and either the 
malondialdehyde (MDA) standard or with tissue homogenates. As mentioned above, 
MDA [CH2(CHO)2] is a highly reactive compound that is formed from the lipid 
peroxidation of PUFA, making it a reactive oxygen species, and a common marker of 
oxidative stress.   
 
Tissue homogenates were prepared by first grinding tissue (brain or liver) into a 
powder using a mortar and pestle and liquid nitrogen. The powder was then weighed out 
into 100 mg samples and placed in 2 ml microcentrifuge tubes. I then added 350 ul of 
degassed water and the tissue was homogenized using a Polytron machine to make a 
1/3.5 x dilution. 100 ul of each dilution was then added to separate 10 ml test tubes and 
mixed with 100 ul of SDS solution (equilibrated to room temperature) and 4mls of colour 
reagent [a mixture of TBA, dilute acetic acid (20%), and dilute NaCl (10%)]. The tubes 
were capped and boiled for an hour in a 100ºC water bath, then cooled on ice for 10 
minutes to stop the reaction, transferred to plastic centrifuge tubes and centrifuged for 10 
minutes at 1,600 * g. Supernatant (150 ul) from each tube was transferred into wells on 
the 96-well assay plate and absorbance readings were taken at 530 nm, using the plate 
spectrophotometer. Absorbances were compared with an MDA standard curve (Figure 6), 
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which was prepared using the MDA standard provided in the assay kit, mixed with water 
to various dilutions.  
 
viii) Calculation of TBARS Concentration 
 
Data reduction was performed according to manufacturer’s instructions, against a 
standard curve of MDA (Cayman Chemical Company, 2010). Blank absorbances were 
subtracted from each tissue absorbance to remove any absorbance associated with 
anything other than tissue composition. Corrected absorbances were used to calculate 
MDA concentration using the formula: MDA (uM) = [Corrected absorbance – y-
intercept/ slope].  The assay kit has a range of 0-50 uM, and typically has an intra-assay 
coefficient of variance between 5.5-7.6%.  
 
ix) Lipid Analysis 
 
 Rat brains were warmed on a metal tray over an ice slurry (mix of ice and water) 
to prevent them from warming to quickly. Brains were then cut in half using a scalpel, 
and half a brain was placed in the -80°C freezer for tissue aldehyde and TBARS analysis. 
The other half was ground into a powder using a mortar, pestle, and liquid nitrogen, 
weighed (300 mg +/- 10 mg) and placed in labeled scintillation vials. The vials were then 
sent to Guelph Lipid Analytical Laboratories in Guelph, Ontario for analysis of the brain 
lipid compositions. Lipids were analyzed by first homogenizing the tissue using a 
Polytron homogenizer. Lipids were then extracted from the samples according to the 
method of Bligh & Dyer (Bligh and Dyer, 1959) in the presence of the internal standard, 
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tritridecanoin. Fatty acid methyl esters were prepared using boron trichloride in methanol, 
and heating the methylation tubes in a boiling water bath. The resulting fatty acid methyl 
esters were analyzed on a Varian 3400 gas-liquid chromatograph, with a 60-m DB-23 
capillary column (0.32 mm internal diameter).   
 
 Experimental livers were prepared in a similar fashion, however due to their 
larger size and homogenous nature, only a small piece had to be cut off each liver (not cut 
in half). Final weights were 300 mg +/- 50 mg.  
 
x) Statistical Analysis 
 
 Concentrations of fatty acids, aldehydes or TBARS were compared using 
ANOVA and Tukey Tests to test for any significant differences between dietary groups. 
Correlational analysis was conducted using linear Pearson regression using a software 
program (Statistica).  
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C) Results 
 
i) Lipid Composition 
Liver 
 Lipid analysis showed that dietary omega-3 PUFA supplementation did 
significantly affect the lipid composition of rat livers, when compared to the palm oil 
CTRL group. Results were reported in percent composition of total liver lipids. The 
percent abundance of 11 out of the 15 PUFA was significantly affected by dietary 
composition (Table 3). Of particular importance was that the concentrations of 
arachidonic acid (C20:4 n-6), EPA (C20:5 n-3), and DHA (C22:6 n-3) were all 
significantly affected (Table 3). Liver AA concentrations were highest in palm oil CTRL 
rats (15.17%), while being significantly reduced (p<0.01) in DHA (5.74%) and EPA-fed 
(6.1%) rats, although ALA supplementation (10.13%) significantly reduced (p<0.05) AA 
concentrations from those of CTRL rats as well (Table 4). In contrast, linoleic acid 
concentrations were unaffected by dietary composition (p>0.05). 
 
 ALA concentrations were significantly increased (p<0.05) in the ALA-
supplemented group (1.34%) when compared to all other groups [DHA (0.24%), EPA 
(0.18%), CTRL (0.1%)] (Table 4). EPA concentrations were significantly increased 
(p<0.005) in the EPA-supplemented group (7.81%) when compared to the palm oil 
CTRL group (0.11%, Figure 7). DHA-supplementation also significantly increased 
(p<0.01) EPA concentrations to 4.23% of total liver lipids (Figure 8), while ALA-
supplementation significantly increased (p<0.05) EPA concentrations from those of the 
palm oil CTRL group to 2.14% (Figure 9). DHA concentrations were significantly 
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increased (p<0.005) in the DHA-supplemented group (15.23%), while EPA and ALA-
supplementation also produced significant increases (p<0.05) from the palm oil CTRL 
group (7.14% and 7.07% respectively, Table 4). It is also important to note that the 
concentration of docosapentaenoic acid (DPA, C22:5 n-3) was significantly higher 
(p<0.05) in EPA-fed groups (2.96%) when compared to other dietary groups (ALA - 
1.2%, DHA - 1%, CTRL - 0.29%, Table 4), as this PUFA is the one that links EPA to 
DHA in the omega-3 fatty acid transition pathway.  
 
Only 2 of the 6 MUFA were significantly affected (p<0.05) by dietary 
composition [physeteric acid (C14:1 n-9) and oleic acid (C18:1 n-9)] (Table 3). Both of 
these MUFA had higher lipid percent concentrations in control groups (0.07% and 28.5% 
respectively), and both had lowest concentrations in the DHA-supplemented group 
(0.026% and 19.7% respectively, Table 4). Oleic acid was found to be significantly 
decreased (p<0.05) in the EPA-supplemented group (22.75%) relative to the palm oil 
CTRL group, but not in the ALA-supplemented group (24.9%, Table 4).  The SFA were 
relatively unaffected by changes in the omega-3 content of their diet (Table 3). Only 2 of 
the 7 SFA measured were found to be significantly affected (14:0 and 15:0).  C14:0 
(myristic acid) was highest in control groups (0.86%) and was found to be significantly 
different (p<0.05) from all omega-3 groups, with DHA (0.53%) again causing the largest 
decrease, followed by EPA (0.6%) and ALA (0.67%, Table 4). C15:0 was actually lowest 
in the palm oil control group (0.09%), while DHA-supplementation (0.13%) caused the 
most significant increase (p<0.05), while ALA-supplementation (0.11%) also caused a 
significant increase (p<0.05, Table 4).  
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Brain 
The brain lipid compositions also had some significant differences between 
omega-3 PUFA supplemented groups and the palm oil CTRL group, as analyzed by 
ANOVA analysis, although not as pronounced as in liver (Table 5). DHA concentrations 
were significantly affected only by supplementation with DHA in the diet (Table 6). The 
DHA-supplemented group had brain DHA concentrations (13.71%) significantly higher 
(p<0.05) than the palm oil CTRL group (11.86%, Figure 10). EPA (C20:5 n-3) 
concentration was significantly increased (p<0.01) in the EPA-supplemented group 
(0.21%) when compared to the palm oil CTRL group (0%, Figure 11). The DHA-
supplemented group (0.09%) also had significantly higher (p<0.05) EPA concentrations 
than ALA-supplemented (0.01%) and palm oil CTRL groups while ALA-fed and control 
groups were not significantly different (p>0.05) from each other (Table 6). DPA (C22:5 
n-3) concentrations were also highest in the EPA-supplemented group (0.71%), again 
significantly higher (p<0.05) than all other groups (Table 6). However, this time DHA 
(0.35%) and ALA-fed (0.31%) groups both showed significantly higher (p<0.05) 
percentages of DPA in their brain lipids than the palm oil CTRL group (0.12%, Table 6). 
The remaining 4 omega-3 PUFA analyzed, including ALA (Figure 12) were not found to 
be significantly affected by diet (p>0.05, Table 5).  
 
Three of the omega-6 PUFA, including linoleic acid, were not significantly affected 
(p>0.05) by dietary composition (Table 5). Arachidonic acid (C20:4, n-6) concentration 
was highest in the palm oil CTRL group (9.61%, Table 6). It was not found to be 
significantly affected (p>0.05) by ALA supplementation (9.34%), however, both palm oil 
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CTRL and ALA-supplemented groups were found to have significantly higher (p<0.05) 
AA concentrations than both EPA (8.22%) and DHA (8.19%) supplemented groups 
(Table 6). The omega-6 PUFA, C22:4 and C22:5 followed a similar pattern to AA, with 
palm oil control groups having significantly higher (p<0.05) concentrations (2.64% and 
0.48% respectively), followed by ALA (2.3%, 0.11%), EPA (1.98%, 0.12%), and DHA-
supplemented groups (1.88%, 0.02%, Table 6).  All omega-3 PUFA supplemented groups 
showed significantly higher (p<0.05) concentrations of the omega-6 PUFA C20:3 than 
the palm oil CTRL group (0.39%, Table 6). Again DHA supplementation (0.62%) 
showed the greatest difference (p<0.05), while EPA supplementation (0.54%) and ALA 
supplementation (0.52%) also had significant (p<0.05), but less pronouced effects (Table 
6). The concentrations of SFA and MUFA were not significantly affected (p>0.05) by 
supplementation with omega-3 fatty acids based on ANOVA analysis (Table 5).  
 
ii) Liver Lipid Composition by Fatty Acid Class 
 
 Comparing total omega-6 and omega-3 fatty acid concentrations, I found that total 
omega-6 PUFA content was significantly decreased (p<0.05) by EPA (15.61%), and 
DHA (15.44%) supplementation, while ALA supplementation (20.32%) did not have a 
significant effect (p>0.05) when compared to the palm oil CTRL group (23.94%, Figure 
13). Total omega-3 PUFA concentrations were significantly increased (p<0.05) by 
omega-3 PUFA dietary supplementation (Figure 14). ALA-supplemented rats did have 
significantly higher (p<0.05) total omega-3 concentrations (11.94%) when compared to 
the palm oil CTRL group (4.83%), however, EPA-supplemented (18.17%) and DHA-
supplemented (20.8%) groups showed a significantly higher increase (p<0.01, Figure 14).  
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I found that EPA supplementation and DHA supplementation significantly 
increased (p<0.01) the ratio of omega-3/omega-6 PUFA (1.18 and 1.35 respectively), 
while ALA supplementation (0.59) increased the ratio to a smaller degree (p<0.05) when 
all groups were compared the palm oil CTRL group (Figure 15). Rats fed control diets 
had an average omega-3/omega-6 PUFA ratio of only 0.2 (Figure 15).  
 
iii) Brain Lipid Composition by Fatty Acid Class 
 
Total brain omega-3 PUFA concentrations were significantly increased (p<0.05) 
by DHA supplementation (14.15%) and EPA supplementation (13.64%), whereas ALA 
supplementation (13.1%) did not significantly differ (p>0.05) from the palm oil CTRL 
group (11.99%, Figure 16).  
 
EPA and DHA supplementation significantly decreased (p<0.05) total omega-6 
PUFA concentrations (12.42% and 12.09%) when compared to the palm oil CTRL group 
(14.35%), and again ALA supplementation (13.59%) failed to significantly differ 
(p>0.05) from the palm oil CTRL group (Figure 17). ALA supplementation did 
significantly increase (p<0.05) the ratio of total omega-3/omega-6 fatty acid 
concentration (0.96) from the palm oil CTRL group (0.84), although not as significantly 
(p<0.01) as EPA (1.1) or DHA (1.7) supplementation (Figure 18).  
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iv) TBARS Analysis 
 
TBARS analysis showed no significant effect (p>0.05) of dietary composition on 
malondialdehyde concentrations in rat livers (Figure 19). Brain TBARS analysis (Figure 
20) also showed no significant difference (p>0.05) in MDA concentrations between 
dietary groups.  
 
v) Headspace Aldehyde Analysis 
 
At room temperature (22°C, Table 7) brain pentanal concentrations were found to 
be significantly higher (p<0.05) in the DHA-supplemented group (44 ppb) when 
compared to the palm oil CTRL group (24 ppb, Figure 21). That was the only aldehyde 
found to be significantly affected (p<0.05) by dietary composition at room temperature 
based on ANOVA and Tukey HSD analysis (Table 7). At 40°C no significant differences 
(p>0.05) were found between any of the dietary groups for any of the aldehydes analyzed 
(Table 8). Again at 60°C a significant difference (p<0.05) was found in brain pentanal 
concentrations (Table 9), although Tukey HSD analysis failed to show a significant 
difference (p>0.05) between any of the 4 groups. Analysis with a less conservative LSD 
test showed a significant difference (p<0.05) between the ALA-supplemented (49 ppb) 
and DHA-supplemented (48 ppb) groups, when compared to the EPA-supplemented 
(33.66 ppb) group (Figure 22). This was the only significant difference found at 60°C 
(Table 9).  
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SIFT-MS analysis of liver aldehyde levels at room temperature showed no 
significant differences (p>0.05) in any of the 4 dietary groups (Table 10). At 40°C 
ANOVA analysis found a significant difference (p<0.05) in butanal concentrations 
(Table 11) between EPA-supplemented (11 ppb) and DHA-supplemented (5 ppb) groups 
(Figure 23). A significant difference (p<0.05) was also found at 60°C for butanal 
concentrations (Table 12), however this time it was found between the ALA-
supplemented (10 ppb) and palm oil CTRL (3 ppb) groups (Figure 24). None of the other 
aldehydes were found to be significantly affected (p>0.05) by dietary composition at 
40°C or 60°C (Tables 11, 12).  
 
Total omega-3 PUFA content did not significantly correlate (p>0.05) with 
propanal concentrations in either liver (Figure 25) or brain, while total omega-6 PUFA 
content did not significantly correlate (p>0.05) with tissue hexanal concentrations (Figure 
26).  
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D) Discussion  
 
To the best of my knowledge, this is the first time that the effects of highly 
purified omega-3 PUFA have been tested in relation to tissue aldehyde concentrations. 
The increased availability of these purified fatty acids allowed me to cost-effectively 
measure the individual effects of each omega-3 fatty acid, and to differentiate between 
them, as opposed to using crude oils. It is important to be able to differentiate between 
the three main types of omega-3 PUFA (ALA, EPA, and DHA), and to be able to discern 
the individual effects of each. Numerous experiments have now suggested differences 
between the actions and therapeutic value of each omega-3 PUFA (see Introduction). It 
may be important for the consumer to look beyond the label, and to read the ingredients 
to determine which omega-3 PUFA are in fact present in the product.  
 
i) Omega-3 Polyunsaturated Fatty Acids in Liver Phospholipids 
 
 My results are in accordance with previous work (von Schacky and Weber, 1985), 
which also found that ALA supplementation, and not EPA or DHA supplementation 
affected ALA concentrations (Table 3). This is because although metabolism can 
generate longer chained omega-3 PUFA from ALA in mammals, it appears unable to 
synthesize the shorter ALA from EPA and DHA. 
 
 Dietary supplementation with EPA led to an increase in the incorporation of EPA 
into liver phospholipids (Figure 7). The observation that ALA-supplementation did not 
significantly increase (p>0.05) EPA lipid concentrations, while DHA supplementation 
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did (p<0.05) when compared to the palm oil CTRL group (Table 4), may seem surprising 
at first, but it has been proposed that DHA may be retro-converted into EPA (von 
Schacky and Weber, 1985). This retro-conversion indicates that DHA may serve as a 
reservoir for EPA in times of low EPA concentrations, possibly through partial β-
oxidation and saturation of the resulting trans-double bond (von Schacky and Weber, 
1985). To date however, researchers have not identified the enzymes needed to perform 
this retro-conversion, and although it appears to occur in von Schacky and Weber’s 
experiment, these results have not been replicated. Perhaps more likely is that the 
increased EPA concentrations found in DHA-supplemented rats could be due to 
impurities in the DHA source used. The source used was 95% pure, and it is likely that 
the remaining 5% could have included EPA.  
 
 DHA concentrations showed a statistically significant increase in lipid DHA 
composition with dietary DHA supplementation, as hypothesized (Figure 8). The 
observation that ALA-supplemented rats did not differ significantly in their DHA 
concentrations from EPA-supplemented rats (Table 4) may indicate that conversion of 
EPA into DHA is just as inefficient as the conversion of ALA into DHA, possibly 
showing that the conversion of EPA to DHA is a rate-limiting step in the overall 
conversion process, which is in accordance with previous works (Harper et al., 2005; 
Stark et al., 2008)  
 
EPA dietary supplementation also had a significant effect on DPA concentrations 
(Table 4), which is in accordance with previous work in human plasma using omega-3 
ethyl esters, where it was also found that EPA, and not DHA, supplementation led to 
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increased concentrations of DPA in platelet phospholipids (von Schacky and Weber, 
1985). This makes sense, as we have seen above (Figure 2), EPA can be converted to 
DHA in a 4-step process, the first of which is the 2 carbon elongation of the omega-3 
EPA (C20:5) into DPA (C22:5). This may be because EPA supplementation leads to 
significantly higher concentrations of DPA. Interestingly, while DHA supplementation 
significantly increased the levels of EPA, it did not significantly affect DPA levels when 
analyzed by an ANOVA test (p>0.05). This supports the conclusion that DHA is not 
retro-converted into EPA. 
  
ii) Arachidonic Acid in Liver 
  
 Arachidonic acid acts as the substrate for a variety of eicosanoids. 
Cyclooxygenase (COX) activity converts AA into PGG2, which is then reduced to PGH2 
by peroxidase activity (Oates et al. 1988). PGH2 then becomes the precursor for various 
prostaglandins (PGD2, PGE2, PGF2, PGI2) and for thromboxane A2 (Figure 27). As 
mentioned earlier, the formation of AA-derived eicosanoids is usually associated with a 
brief, explosive burst of synthesis of eicosanoids, that if too great, has been associated 
with many inflammatory diseases (Lands, 1992). It has become clear that managing AA-
derived eicosanoid concentrations is of great importance. 
 
 My results show that AA concentrations can be managed by dietary omega-3 
PUFA supplementation in liver (Table 4). Rats fed the palm oil CTRL diet had on 
average 15.2% of their lipids made up of arachidonic acid (Table 4). This value is at the 
upper range of what  past studies have found (Neuringer et al., 1988). Arachidonic acid is 
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present in all biological membranes, and represents approximately 5-15% of the total 
fatty acid composition of most tissue phospholipids (Neuringer et al., 1988). The high 
percentage found is probably indicative of the average Western diet, containing high 
amounts of SFA and oleic acid (n-9 MUFA), along with about 10% of their fat source 
coming from omega-6 PUFA, with little to no omega-3 PUFA in the diet.  
 
 In contrast to the palm oil control group, ALA-supplemented rats were found to 
significantly decrease AA concentrations (Figure 9), indicating that flax seed, and 
consequently ALA, may be sufficient alone to decrease AA concentrations in liver. 
Whether this action is through the limited conversion of ALA to EPA and DHA, or if 
ALA is exerting some other protective effect remains to be determined. It has been shown 
that not only do ALA and LA compete for the same ∆4 and ∆6 desaturases, but that the 
omega-3 PUFA has a greater affinity for these enzymes (Rose and Connolly, 1999). This 
leads to a reduction in AA production from LA in the presence of enough ALA (Rose and 
Connolly, 1999). The significance found in rat livers may also be in part due to the fact 
that both the omega-3 PUFA, ALA, and the omega-6 PUFA, LA, are metabolized into 
their respective longer chain fatty acids, for the most part in the liver (Rose and Connolly, 
1999), leading to an increase in the concentrations of DHA, and in particular EPA, in the 
liver, which is consistent with a study (Goyens et al., 2006) which found 6% of ALA 
from the plasma phospholipid pool used was converted into EPA. It has become apparent 
that EPA can displace AA from membrane phospholipids.  
  
 Supplementation with ALA significantly reduced (p<0.05) the amount of 
arachidonic acid concentrations, however EPA and DHA supplementation produced 
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greater and statistically significant decreases (p<0.01) than ALA (Table 4). It has been 
established that competition exists between AA and EPA to be converted by COX and 
LOX enzymes into their respective eicosanoids (Rose and Connolly, 1999; Lands, 1992). 
As with AA, EPA is converted into PGG, and then reduced into PGH, which is then 
further metabolized into PGE, PGI, and thromboxane A (Figure 28), except EPA is 
converted into 3-series prostanoids, while AA is converted into 2-series prostanoids with 
much more inflammatory effects (Lands, 1992).  
 
  My findings (Figure 7) support earlier work (Calder, 2002) which found that 
EPA supplementation decreased AA concentrations in liver by displacing them from 
membranes, as well as decreasing concentrations of AA-derived eicosanoids.  My results 
are also in agreement with a study done in 2009 (Shearer et al., 2010), using purified 
omega-3 PUFA ethyl esters, which found that EPA supplementation decreased AA 
concentrations by an average of 20%. They also found that these purified omega-3 PUFA 
lowered the LOX-catalyzed, AA-derived HODE isomers by 18%, again indicative of an 
increase in the omega-3/omega-6 PUFA ratio of substrates (Shearer et al., 2010).  
 
 There is evidence that DHA may decrease AA phospholipid levels by decreasing 
Δ6 and Δ5 desaturation, thereby decreasing the formation of AA-derived eicosanoids 
(Grimsgaard et al., 1997), however unlike EPA, DHA is not of the same chain length as 
AA, and does not produce eicosanoids that compete with those of AA, although it does 
produce its own oxylipins. Not only did I see a significant reduction (p>0.05) in AA 
concentrations with DHA supplementation (Figure 8), but I actually saw a slight (though 
not statistically significant) decrease AA concentrations in DHA-supplemented rats from 
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EPA-supplemented rats (Table 4).  Although DHA is 2 carbons longer than AA, it has 
been found to have a similar effect to EPA in displacing AA from membrane 
phospholipids (Calder, 2002). DHA supplementation has also been found to decrease 
omega-6 eicosanoids and HODE isomers, while having no effect on LOX-catalyzed, 
EPA-derived HETE isomers (Shearer et al., 2010). Whether this reduction is through 
competition for enzymes or phospholipases remains to be determined, but it is becoming 
clear that DHA supplementation is as capable as EPA at reducing AA concentrations in 
liver membrane phospholipids, and that both marine-derived omega-3 PUFA, DHA and 
EPA, are more likely to have AA lowering capabilities than the flaxseed-derived ALA.  
 
iii) Other Omega-6 Polyunsaturated Fatty Acids in Liver Phospholipids 
 
Two of the omega-6 PUFA were not significantly affected by diet (p>0.05), while 
other did not follow any specific pattern (Table 3), indicating that omega-3 PUFA 
supplementation does not appear to alter the concentrations of very long chain omega-6 
PUFA. Of note was that the 18-carbon precursor for arachidonic acid, linoleic acid, did 
not significantly differ in its overall percentage with any omega-3 PUFA supplementation 
(Table 3). This is consistent with the findings in plasma and platelet phospholipids (von 
Schacky and Weber, 1985; Shearer et al., 2010).  
 
iv) Saturated and Monounsaturated Fatty Acids in Liver Phospholipids  
 
 The observation that the percentages of only 2 of the 7 SFA were significantly 
affected by omega-3 PUFA dietary supplementation (Table 3) is not a surprise, as we 
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know that omega-3 PUFA compete with omega-6 PUFA to be transformed into 
secondary products, and not with SFA. We know that omega-3 PUFA accumulate in 
phosphatidylethanolamine, phosphatidylcholine, and in triglycerides (de Bravo et al., 
1991). Unsaturated fatty acids in de novo synthesis of triglycerides are usually placed 
originally at the sn-2 position, but are then replaced by PUFA through the actions of 
phospholipid retailoring acyltransferases (Lands, 1992). Because of this, omega-3 PUFA 
usually occupy the sn-2 position of triglycerides, while SFA occupy the sn-1 and sn-3 
positions (Zock et al., 1995). This could explain why we do not see significant decreases 
in liver phospholipid SFA content.  
 
 Only 2 of the 6 MUFA were significantly affected (p<0.05) by dietary 
supplementation (Table 3). However, both C14:1 and C18:1 are of much smaller chain 
length then DHA, and it is uncertain if there is any physiological significance to this 
finding, and more work on the interactions between MUFA and PUFA are required.  
 
v) Liver Lipid Composition by Fatty Acid Class  
 
 My finding that total omega-6 PUFA content was significantly decreased 
(p<0.05) by EPA and DHA supplementation, while ALA supplementation did not have a 
significant effect (p>0.05) when compared to the palm oil control groups (Figure 13) is   
important , and is in agreement with what I hypothesized. The omega-6 PUFA lowering 
advantage of fish oil derived omega-3 PUFA, EPA and DHA, over the flax seed derived 
ALA, has been shown in numerous studies (Shearer et al., 2010; Lands, 1992; Anderson 
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and Ma, 2009), and may contribute to the various disease prognosis improvements we see 
with omega-3 PUFA dietary supplementation.  
 
 ALA-supplemented rats did have significantly higher total liver omega-3 PUFA 
lipid concentrations when compared to palm oil control groups (p<0.05), however, EPA 
and DHA-supplemented groups showed further decreases (p<0.01, Figure 14). This 
finding again suggests a benefit of marine-derived omega-3 PUFA sources over flax-seed 
sources. 
 
 Several studies have suggested that the ratio of omega-3 to omega-6 PUFA is of 
greater importance than the individual concentrations of each fatty acid class (Lands, 
2008; Okuyama, 2001; Griffin 2008; Tribole et al., 2006). As mentioned above, both 
PUFA compete for the same enzymes to be transformed into their respective eicosanoids, 
and the amount of substrate of each PUFA available appears to directly correlate with the 
amount of each type of eicosanoid produced (Rose and Connolly, 1999; von Schacky et 
al., 1985; Neuringer et al., 1988; Lands 1992). Again, it was found that EPA and DHA 
significantly increased (p<0.01) this ratio to the same degree, while ALA significantly 
increased (p<0.05) the ratio to a smaller degree compared to ratios of palm oil CTRL rats 
(Figure 15). Rats fed the palm oil CTRL diet showed an average omega-3/omega-6 in 
their liver lipids still higher than that of the average Western diet, usually between 0.1 
and 0.025, while ALA supplementation produced liver lipids closer to the 1:1 ratio that 
has been suggested (Lands, 2005) to be optimal based on the evolutionary human diet. 
However, EPA and DHA supplementation produced liver lipids with a greater than a 1:1 
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ratio in favour of omega-3 PUFA (Figure 15). Again an added benefit of marine omega-3 
PUFA over ALA, in modifying omega-6 eicosanoid production, was found.  
 
vi) Omega-3 Polyunsaturated Fatty Acids in Brain Phospholipids 
 
Although DHA supplementation significantly increased (p<0.05) DHA 
concentrations (Figure 10), EPA and ALA-supplementation did not (p>0.05) when 
compared to control groups (Table 6). Unlike in liver, I did not see a  decrease in lipid 
DHA concentrations with the absence of DHA from the diet,  but only a small decrease in 
DHA concentrations, although significant (Figure 10). In fact, it appears as though the 
brain has a homeostatic mechanism for maintaining high DHA concentrations even in the 
absence of DHA in the diet (Table 6). DHA makes up about one third of the total fatty 
acid content of ethanolamine and serine phospholipids in cerebral gray matter (Neuringer 
et al., 1988), and its concentrations appear to be maintained regardless of dietary omega-
3 PUFA intake (Neuringer et al., 1988). Whether this is due to a much slower fatty acid 
turnover rate in the brain, due to the importance of DHA in maintaining proper brain 
function, or for another reason remains to be determined, but this observation leads us to 
an interesting avenue for future research to follow.    
 
Brain EPA concentrations were significantly increased (p<0.05) by dietary 
supplementation with EPA and DHA (Table 6), however actual EPA abundance and 
increase was much lower than in liver (Figure 11). This finding may help explain PUFA 
composition in brain. It appears as though the brain has a mechanism for keeping EPA 
out of its phospholipids, even when high concentrations are provided through the diet. 
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Previous research (Chen et al., 2011) has shown that EPA appears to be limited in brain 
phospholipids, and that this is probably due to extensive metabolism of EPA in brain, in 
part by β-oxidation, upon entry into the brain and upon de-esterification from 
phospholipids. However, the statistically significant increase in EPA concentrations with 
EPA supplementation (Figure 11), although small, appears to be sufficient enough to 
cause a significant (although much smaller than in liver) decrease in AA concentrations. 
Perhaps only a small increase in EPA, or decrease in AA, percent lipid composition is 
required to produce drastic alterations in brain function. This may be why the brain 
appears to maintain very low EPA concentrations, even when high amounts are fed in the 
diet (Figure 11).  
 
ALA supplementation failed to significantly increase (p>0.05) EPA or DHA 
concentrations compared to those of palm oil control groups (Figure 12), again showing 
the importance of consuming EPA and DHA directly, and not relying solely on the 
conversion of ALA to obtain the longer chained omega-3 PUFA. A similar effect is also 
found when looking at brain ALA concentrations. A diet high in ALA concentrations 
failed to increase ALA concentrations (Figure 12). This suggests that ALA is may be 
rapidly converted into longer-chained PUFA in brain, or that it may have a potentially 
harmful effect on the brain, as discussed about with EPA, although future study is needed 
to justify these theories. 
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vii) Omega-6 Polyunsaturated Fatty Acids in Brain Phospholipids 
 
As in liver , brains of DHA and EPA-supplemented rats had significantly (p<0.05) 
lower arachidonic acid concentrations than the ALA-supplemented and palm oil CTRL 
groups (Table 6). EPA’s ability to significantly decrease AA concentrations (Figure 11) 
may show that only a small amount of EPA in the brain can have significant effects on 
AA metabolism (Philbrick et al., 1987).These alterations in lipid composition may alter 
membrane fluidity, cellular responses, ion transport, as well as the synthesis of AA- and 
EPA-derived eicosanoids (Philbrick et al., 1987), which may help to explain why the 
brain appears to be limiting EPA concentrations.  
 
The increased incorporation of DHA into brain phospholipids may account for the 
decrease in AA concentrations with DHA supplementation (Figure 10), which has been 
suggested to have anti-bipolar effects (Bazinet et al., 2006). It appears as though DHA 
supplementation may have the same ability as EPA supplementation to decrease AA 
uptake (Table 6), and potentially metabolism and eicosanoid production. Again, I found a 
significant difference (p<0.05) between marine and flaxseed generated omega-3 PUFA 
(Table 6), which may be due to the fact that ALA is converted to EPA, and consequently 
DHA, predominantly in the liver (Rose and Connolly, 1990). As suggested above, this 
may be the reason that I found a significant effect of ALA supplementation on AA 
concentrations in rat livers (through increased EPA and DHA competing with AA), and 
would be supported by the fact that I did not see a significant increase (p>0.05) in EPA 
concentrations with ALA supplementation in brain (Figure 12).  
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viii) Saturated and Monounsaturated Fatty Acids in Brain Phospholipids 
 
 The observation that dietary omega-3 PUFA supplementation failed to 
significantly affect (p>0.05) any of the seven SFA (Table 5) may not be surprising, given 
that, as I mentioned above, omega-3 PUFA and SFA tend to occupy different positions 
when incorporated into triglycerides, possibly preventing omega-3 PUFA from replacing 
SFA in the lipid bilayers of mammalian membranes (Lands, 1992).  
 
 The finding that omega-3 PUFA dietary supplementation failed to significantly 
affect (p>0.05) the levels of any of the six MUFA (Table 5) is more surprising, as 
unsaturated fatty acids are usually replaced by highly unsaturated fatty acids at the sn-2 
position in triglycerides (Lands, 1992). It appears as though this phospholipid 
acyltransferase retailoring is either not significant enough to affect overall concentrations 
of MUFA, or that perhaps the in vivo production of these MUFA by the body increases to 
ensure that their concentrations do not decrease dramatically in the presence increased 
omega-3 PUFA concentrations, indicating a possible increased importance of MUFA in 
brain as opposed to liver, possibly to protect against age-related cognitive decline 
(Solfrizzi et al., 1999), although the relatively small change in omega-3 PUFA 
concentrations observed may have been insufficient to impact MUFA concentrations.  
 
ix) Brain Phospholipid Composition by Fatty Acid Class 
 
 Much like in liver, EPA and DHA supplementation had the greatest ability to 
increase (p<0.05) total brain omega-3 PUFA concentrations (Figure 16), however unlike 
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in liver, ALA supplementation did not significantly result in differences (p>0.05) in total 
omega-3 PUFA concentrations from those of palm oil control rats (Figure 16). The 
increases in total omega-3 PUFA concentrations with EPA and DHA supplementation 
again were balanced by significant decreases (p<0.05) in total omega-6 PUFA 
concentration compared to ALA-supplemented and palm oil CTRL groups (Figure 17).  
This may be explained by the fact that most of the conversion of ALA into the longer-
chained omega-3 PUFA occurs in the liver (Rose and Connolly, 1990). Again, it is worth 
mentioning that the changes, while statistically significant, were much lower in brain than 
in liver. Although it has been shown that both AA and DHA have a rapid turnover rate in 
rodent brains (Rapoport, 2008), it appears from my results as though the brain more 
strictly regulates its fatty acid content than liver, even when dietary conditions are 
changed.  
 
x) TBARS Analysis 
 
Changes in MDA concentrations have been associated with various diseases, 
including schizophrenia (Mahadik et al., 2006). My results provide some potentially 
interesting insight into the relationship of omega-3 PUFA and oxidative stress.   
 
 Contrary to my hypothesis, my results failed to show any significant difference 
(p<0.05) in liver or brain TBARS concentrations with dietary omega-3 supplementation 
of any kind (Figures 19, 20). I anticipated to see increases in oxidative stress in rats fed 
diets high in omega-3 PUFA, in comparison to the palm oil CTRL group, as omega-3 
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PUFA have more double bonds than SFA and MUFA, which should make them more 
susceptible to lipid peroxidation by ROS (Tsuduki et al., 2011).  
  
 Previous works on omega-3 PUFA and oxidative stress have lead to similar 
findings to mine, with further reductions in oxidative stress being found with omega-3 
PUFA treatment (Barbosa et al,. 2003; Wu et al., 2004). Although PUFA contain more 
double bonds (a preferred site of attack for ROS) and show an increased propensity for 
lipid peroxidation in vitro, they do not show increased lipid peroxidation and oxidative 
stress in vivo. My results are consistent with such conclusions and I will review some of 
the mechanisms explaining how this may occur.  
 
 When we think of oxidative stress, we think of an antioxidant defense system 
incapable of combating the level of ROS in the tissue. This leads us to the possibility that 
omega-3 PUFA have the capability to reduce the production of free radicals. We know 
that EPA competes with AA to be transformed into their respective metabolites, and it 
has been proposed that this competition, and subsequent reduction in AA-derived 
metabolites, specifically leukotriene B4 through the LOX pathway, may be one of the 
most important ways that omega-3 PUFA can reduce oxidative stress (Barbosa et al., 
2003). It has been widely documented that the reduction of AA-derived metabolites by 
omega-3 PUFA competition has shown beneficial effects in a wide range of situations 
(Rose and Connolly, 1990; Lands, 1992), and this could be another benefit of this 
competition.  
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It is possible that omega-3 PUFA may be exerting a positive effect by boosting 
the antioxidant defense system. It has been proposed that omega-3 PUFA themselves may 
act as free radical scavengers, protecting the body against the overall effect of oxidative 
stress (Barbosa et al., 2003). Not only did Barbosa and colleagues find a reduction in 
plasma lipid peroxide formation, but they also found that omega-3 PUFA treatment lead 
to a significant increase in plasma antioxidant capacity (Barbosa et al., 2003). This 
hypothesis has been supported by another study (Palozza et al., 2002), who studied the 
effects of omega-3 PUFA on oxidative stress and antioxidant levels in human 
erythrocytes (Palozza et al., 2002). During their research they found that omega-3 PUFA 
supplementation not only changed lipid composition, but was also found to modulate α-
tocopherol (a form of vitamin E, preferentially absorbed in humans) concentration. It was 
found that concentrations of this antioxidant increased with omega-3 PUFA 
supplementation after 30 days in red blood cell membranes (Palozza et al., 2002). This 
presents a very interesting solution to the questions raised by their apparent ability to 
reduce oxidative stress. These results suggest the existence of a membrane mechanism of 
homeostasis that functions to maintain adequate tissue concentrations of vitamin E (α-
tocopherol, a potent antioxidant) to avoid the increased lipid peroxidation that results 
from a higher membrane omega-3 PUFA content (Palozza et al., 2002). This would help 
to explain the lack of dietary influence found in my results after 8 weeks (Figures 19, 20), 
through the increased concentration of α-tocopherol, although future work would be 
required to test this hypothesis. 
 
However, Palozza et al. 2002 also found that while no changes in lipid 
peroxidation were noticed after 30 days of omega-3 PUFA supplementation, after 180 
 57 
 
days of omega-3 PUFA supplementation lipid peroxidation was significantly increased in 
red blood cell membranes, combined with a return to baseline α-tocopherol 
concentrations (Palozza et al., 2002). This decrease in α-tocopherol concentrations after 
180 days led to increased lipid peroxidation in their study (Palozza et al., 2002), and may 
help to explain why no significant increases were found in my experiment (Figures 19, 
20), where the feeding period was only 8 weeks.  
 
Although these are both hypotheses that would make sense, the mechanisms by 
which they accomplish either or both of these processes need to be explained. This leads 
me to suggest that a combination of omega-3 PUFA and antioxidants in the diet may be 
the best way to obtain the cardiovascular benefits of omega-3 PUFA, while limiting their 
potential negative effects. This combination has been suggested by other researchers as 
well (Mahadik et al., 2006). 
 
xi) Tissue Aldehyde Analysis 
 
 SIFT-MS was used to analyze the headspace aldehyde concentrations of my 
tissue. As with my TBARS analysis, I hypothesized that the extra double bonds in the 
marine-type omega-3 dietary supplemented groups would lead to increased headspace 
aldehyde concentrations (Tsuduki et al., 2011), specifically, that increases in omega-3 
fatty acid consumption would lead to increased propanal concentrations in tissue (Shen et 
al., 2007), while decreasing hexanal concentrations through a decrease in dietary omega-
6 fatty acid content (Jaar et al., 1999).  
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Liver 
  
According to ANOVA analysis, only liver butanal headspace concentrations were 
found to be significantly affected (p<0.05) by omega-3 dietary content (Tables 10, 11, 
12). However, the variability in my aldehyde concentration data precludes any conclusion 
that dietary omega-3 PUFA supplementation significantly affected aldehyde 
concentrations. The use of a Bonferroni’s correction to correct for the multiple analyses 
performed, may have eliminated statistical significance found.  
 
 No trend was found when looking at liver propanal concentrations. In fact, total 
omega-3 PUFA content did not significantly correlate with propanal concentrations in 
liver (Figure 25) or brain, and the same can be said for tissue acetaldehyde 
concentrations. Total omega-6 PUFA content also did not significantly correlate with 
hexanal concentrations in either liver (Figure 26) or brain. These findings suggest that 
omega-3 PUFA dietary intake has no significant effect on aldehyde concentrations in the 
liver and brain tissue of rats at dietary concentrations used in my experiment. My findings 
differ from those of previous studies using fish meal as a source of omega-3 PUFA, 
which consistently found a positive correlation between dietary omega-3 PUFA 
supplementation and brain aldehyde and plasma acetaldehyde concentrations (Tampier et 
al., 1985; Quintanilla et al., 1993; Tampier and Quintanilla, 2002; Quintanilla et al., 
2002). This leads to the hypothesis that the 95% pure omega-3 PUFA used in our study, 
might not only allow us to investigate the effects of individual omega-3 PUFA, but may 
also produce different effects than combination omega-3 fish sources. It is possible that 
the positive correlations made in previous studies may have been due to something other 
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than the omega-3 PUFA provided in the fish meal diets. As with the TBARS analysis, it 
is also possible that the lack of significant in headspace tissue aldehyde concentrations 
between dietary groups is due to the relatively short feeding period (Barbosa et al., 2003), 
which may coincide with an initial increase in aldehyde metabolism in the short-term by 
the body, to defend against the toxic aldehydes. 
 
Brain  
 
As with liver butanal concentrations, I propose that the significant differences 
found at room temperature and 60°C (Figures 21, 22), are more due to a statistical 
anomaly, and are not indicative of any physiological significance, and may have been 
eliminated by using a Bonferroni’s correction. 
 
 Interestingly enough, DHA and EPA supplementation did not significantly 
increase brain propanal concentrations (Figure 25) or decrease brain hexanal 
concentrations (Figure 26) as hypothesized. Brain acetaldehyde concentrations did not 
follow any significant pattern either (Tables 7, 8, 9). These results suggest no effect of 
purified omega-3 supplementation on tissue aldehyde concentrations in brain, and along 
with the results found in liver, indicate that aldehydes may indeed be a stable biomarker 
of oxidative stress (Fuchs et al., 2009). Further studies may want to use larger sample 
sizes, and longer feeding periods to test for a potential short-term increase in aldehyde 
metabolism leading to misleading results in shorter feeding periods.  
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E) Conclusion 
 
Liver and brain lipid compositions are not only directly affected by total omega-3 
PUFA consumption, but also by which types of omega-3 FAs are consumed. My results 
support previous works (Gerster, 1998; Goyens et al., 2006) showing that ALA 
consumption alone is insufficient in increasing concentrations of the long-chained 
omega-3 PUFA, EPA and DHA, when compared to EPA and DHA supplementation 
themselves. ALA also appears incapable of increasing EPA concentrations, or decreasing 
AA concentrations in my study, enough to affect competition between these two 
substrates for COX and LOX enzymes. This may help explain why dietary ALA 
supplementation has not shown the same cardiovascular benefits as fish oil 
supplementation (Anderson and Ma, 2009). Interestingly enough, my results suggest that 
the inclusion of EPA alone in the diet may not be able to produce sufficiently high DHA 
concentrations to maintain proper brain structure (Holman, 1998; Fitzpatrick, 2002), 
while dietary DHA supplementation appears unable to produced EPA concentrations as 
high as consuming EPA itself does.  
 
Interestingly, ALA and EPA supplementation seems to have less of an effect on 
ALA and EPA concentration in brain than in liver, while DHA concentrations appear to 
be maintained in brain regardless of dietary composition in my study. These results will 
need to be reproduced to determine whether this consistently occurs, and  if this is a sign 
that the brain has a mechanism for limiting EPA concentration, and if so, is this  to limit 
competition with arachidonic acid. DHA concentrations are probably maintained due to 
their importance in maintaining proper brain development and function (Holman, 1998).  
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It appears as though, EPA and DHA consumption is necessary to gain the 
cardiovascular benefits found in various studies on omega-3 PUFA in liver, but that DHA 
is the only omega-3 PUFA that is important structurally in brain, as it appears to be 
conserved in brain tissue even under low omega-3 PUFA consumption. 
 
My results did not show any significant effects of omega-3 PUFA dietary 
consumption on headspace aldehyde or TBARS concentrations, indicating that diet may 
not affect the concentrations of either. On the basis of my work, it seems as though 
aldehydes may provide a reliable biomarker for oxidative stress, as they appear to be 
unaffected by dietary composition. Certain aldehydes also appear to be a good marker for 
oxidative stress, which is associated with various diseases, such as cancer (Fuchs et al., 
2009). It is important to note that in my study rats were fed for 8 weeks, and that based on 
the work of other studies, I may have found different results if dietary omega-3 PUFA 
supplementation was carried on for a greater period of time. I cannot rule out an initial 
boost in the body’s natural antioxidant defense system (Barbosa et al. 2003) as the cause 
for the lack of significant differences in tissue aldehyde levels between dietary groups. It 
is possible that this defense was able to counter the increased production of LP-DA 
resulting from the increased lipid peroxidation of the PUFA through increased aldehyde 
metabolism, or that this boost was able to limit lipid peroxidation itself by neutralizing 
ROS.  
 
Future studies will need to focus on using highly purified omega-3 PUFA, as used 
in my study, to test the effect of dietary omega-3 PUFA supplementation on aldehyde 
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concentrations over a period greater than 4 months. This will help to determine whether 
my findings are an indication of the individual effects of the highly purified omega-3 
PUFA used (instead of the crude oils used in the past), or whether they are due to a short-
term boost in the body’s endogenous defense system. 
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Figures and Tables 
 
Table 1: List of chemical structure, scientific and common names for each fatty acid 
analyzed.  
Chemical Formula Scientific Name Common Name 
C14:0 tetradecanoic acid Myristic acid 
C14:1 N/A Physeteric acid 
C15:0 N/A N/A 
C16:0 hexadecanoic acid Palmitic acid 
C16:1 9-hexadecenoic acid Palmitoleic acid 
C18:0 octadecanoic acid Stearic acid 
C18:1 9-octadecenoic acid Oleic acid 
C18:2 n-6 9,12-octadecadienoic acid Linoleic acid (LA) 
C18:3 n-6 6,9,12-octadecatrienoic acid Gamma-linoleic 
acid C18:3 n-3 9,12,15-octadecatrienoic acid Alpha-linoleic acid 
(ALA) C18:4 n-3 N/A Stearidonic acid 
C20:0 eicosanoic acid Arachidic acid 
C20:1 9-eicosenoic acid Gadoleic acid 
C20:2 n-6 N/A N/A 
C20:3 n-6 N/A Dihomo-gamma-
linolenic acid C20:4 n-6 5,8,11,14-eicosatetraenoic acid Arachidonic acid 
(AA) C20:3 n-3 N/A N/  
C20:4 n-3 N/A N/A 
C20:5 n-3 5,8,11,14,17-eicosapentaenoic acid EPA 
C22:0 docosanoic acid Behenic acid 
C22:1 13-docosenoic acid Erucic acid 
C22:2 n-6 N/A N/A 
C22:4 n-6 N/A N/A 
C22:5 n-6 N/A N/A 
C22:5 n-3 N/A DPA 
C22:6 n-3 4,7,10,13,16,19-docosahexaenoic 
acid 
DHA 
C24:0 tetracosanoic acid Lignoceric acid 
C24:1 N/A Nervonic acid 
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Figure 1: Lipid bilayer of the cell membrane showing integral membrane proteins 
responsible for transportation across membrane bilayer (Sparksnotes 2012) 
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Table 2: Fatty acid composition (%) of some common sources of dietary oils (Edwards, 
2007). 
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Figure 2: Synthesis of EPA and DHA from 18-carbon ALA through desaturation and 
elongation events (Possick 2010) 
 
 
Figure 3: Conversion of different PUFA into different eicosanoids, done by same COX 
and LOX enzymes. Depending on the precursor fatty acid present, different types of 
eicosanoids are generated. (Anonymous, 2011) 
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Figure 4: Degredation of lipid peroxides, producing malondialdehyde, 4-HNE and other 
aldehydes (Alves de Almeida et al., 2007). 
Figure 5: Schematic diagram of a SIFT-MS machine showing sample microwave 
resonator ion source, which produces precursor ions that react with samples introduced 
downstream either through breath or headspace analysis. Ions react and are carried along 
the flow tube by helium gas, and finally sampled by the downstream quadrupole mass 
spectrometer (Spanel et al. 2005).  
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Table 3: ANOVA results testing for significant differences in liver lipid compositions 
between dietary groups. F-values are used to find significant differences between dietary 
groups. *indicates a statistically significant difference was found between groups 
(p<0.05). Tukey Tests were then performed to determine which dietary groups produced 
the differences. LA – linoleic acid, ALA – alpha-linolenic acid, AA – arachidonic acid, 
EPA – eicosapentaenoic acid, DHA – docosahexaenoic acid 
 
Fatty Acid Df MS F P 
C14:0* 3 0.155 7.76 0.001 
C14:1* 3 0.004 3.93 0.019 
C15:0* 3 0.004 3.94 0.019 
C16:0 3 3.620 0.80 0.505 
C16:1 3 4.268 2.29 0.101 
C18:0 3 7.266 2.78 0.061 
C18:1* 3 103.6 7.73 0.001 
C18:2 n-6 LA 3 5.813 2.04 0.132 
C18:3 n-6* 3 0.019 3.42 0.032 
C18:3 n-3* ALA 3 2.476 44.1 <0.001 
C18:4 n-3* 3 0.001 3.91 0.019 
C20:0 3 <0.001 0.40 0.754 
C20:1 3 0.004 1.27 0.305 
C20:2 n-6 3 0.001 1.65 0.202 
C20:3 n-6* 3 0.298 10.6 <0.001 
 C20:4 n-6 AA* 3 150.2 42.4 <0.001 
C20:3 n-3* 3 0.002 22.5 <0.001 
C20:4 n-3* 3 0.003 9.96 <0.001 
C20:5 n-3 EPA* 3 85.55 36.9 <0.001 
C22:0 3 0.001 2.40 0.090 
C22:1 3 <0.001 0.99 0.410 
C22:2 n-6* 3 0.002 7.52 0.001 
C22:4 n-6 3 0.001 0.77 0.522 
C22:5 n-6* 3 1.424 74.8 <0.001 
C22:5 n-3* 3 10.38 14.6 <0.001 
C22:6 n-3 DHA* 3 162.1 52.8 <0.001 
C24:0 3 0.940 0.85 0.477 
C24:1 3 0.001 0.53 0.660 
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Table 4: Mean liver lipid composition (%) +/- one standard deviation of each fatty acid 
for each dietary group (EPA, DHA, ALA, CTRL). *indicates a significant at p<0.05, ** 
indicates a significance at p<0.01, and *** indicates a difference at p<0.005, as compared 
to palm oil control groups from Tukey Test analysis. CTRL = palm oil control, EPA = 
eicosapentaenoic acid, DHA = docosahexaenoic acid, ALA = alpha-linolenic acid. 
 
 EPA DHA ALA CTRL 
C14:0* 0.6 +/- 0.1* 0.52 +/- 0.11* 0.68 +/- 0.13 0.86 +/- 0.2 
C14:1* 0.03 +/- 0.02 0.02 +/- 0.01* 0.03 +/- 0.02 0.07 +/- 0.05 
C15:0* 0.1 +/- 0.07 0.13+/- 0.05* 0.11 +/- 0.07 0.09 +/- 0.07 
C16:0 27.1 +/- 2.06 27+/- 2.4 26.08 +/- 1.4 25.69 +/- 2.44 
C16:1 3.35 +/- 1.31 2.8 +/- 1.1 3.56 +/- 1.03 4.59 +/- 1.84 
C18:0 10.8 +/- 1.6 13 +/- 1.2 11.62 +/- 2.09 10.66 +/- 1.45 
C18:1* 22.75 +/- 2.36* 20+/- 2.8* 24.9 +/- 5.61 28.51 +/- 3.27 
C18:2 n-6  8.63 +/- 1.83 8.5 +/- 1.1 9.04 +/- 1.17 7.04 +/- 2.24 
C18:3 n-6* 0.1 +/- 0.03* 0.15 +/- 0.12 0.1 +/- 0.03* 0.21 +/- 0.08 
C18:3 n-3 * 0.18 +/- 0.05 0.24 +/- 0.27 1.34 +/- 0.41* 0.1 +/- 0.04 
C18:4 n-3* 0.02 +/- 0.01 0.03 +/- 0.01 0.03 +/- 0.02* 0 +/- 0 
C20:0 0.06 +/- 0.01 0.06 +/- 0.01 0.06 +/- 0.01 0.06 +/- 0.01 
C20:1 0.25 +/- 0.06 0.22 +/- 0.03 0.26 +/- 0.04 0.28 +/- 0.08 
C20:2 n-6 0.1 +/- 0.02 0.11 +/- 0.01 0.13 +/- 0.04 0.12 +/- 0.03 
C20:3 n-6* 0.57 +/- 0.14 0.87 +/- 0.18* 0.8 +/- 0.22* 0.44 +/- 0.12 
C20:4 n-6 * 6.1 +/- 0.85** 5.7 +/- 0.74** 10.13 +/- 2.33* 15.17 +/- 2.7 
C20:3 n-3* 0.01 +/- 0.01 0 +/- 0 0.04 +/- 0.01* 0 +/- 0.01 
C20:4 n-3* 0.04 +/- 0.02 0.04 +/- 0.01 0.06 +/- 0.03* 0.01 +/- 0.01 
C20:5 n-3 * 7.81 +/- 2.72*** 4.2 +/- 1.1** 2.14 +/- 0.44 0.11 +/- 0.05 
C22:0 0.07 +/- 0.01 0.01 +/- 0.01 0.07 +/- 0.02 0.06 +/- 0.01 
C22:1 0 +/- 0 0.02 +/- 0.01 0 +/- 0 0 +/- 0 
C22:2 n-6 0.02 +/- 0.01 0.05 +/- 0.03 0 +/- 0 0.02 +/- 0.01 
C22:4 n-6 0.07 +/- 0.02 0.06 +/- 0.01 0.08 +/- 0.04 0.07 +/- 0.02 
C22:5 n-6* 0.01 +/- 0.02*** 0.03 +/- 0.01*** 0.03 +/- 0.02*** 0.87 +/- 0.26 
C22:5 n-3* 2.97 +/- 1.53* 1 +/- 0.25 1.27 +/- 0.48 0.27 +/- 0.17 
C22:6 n-3 * 7.14 +/- 0.77* 15.3 +/- 2.6*** 7.07 +/- 2.22* 4.33 +/- 0.88 
C24:0 0.93 +/- 2.02 0.27 +/- 0.05 0.24 +/- 0.07 0.22 +/- 0.03 
C24:1 0.17 +/- 0.07 0.16 +/- 0.01 0.14 +/- 0.04 0.15 +/- 0.02 
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Table 5: ANOVA results testing for significant differences in brain lipid compositions 
between dietary groups. F-values are used to find significant differences between dietary 
groups. *indicates a significant difference was found between groups (p<0.05). LA = 
linoleic acid, AA = arachidonic acid, ALA = alpha-linolenic acid, EPA = 
eicosapentaenoic acid, DHA = docosahexaenoic acid 
Fatty Acid Df MS F P 
C14:0 3 0.001 0.657 0.586 
C14:1 3 0.040 1.287 0.299 
C15:0 3 0.001 0.107 0.955 
C16:0 3 0.150 0.130 0.940 
C16:1 3 0.003 0.741 0.537 
C18:0 3 0.190 0.950 0.431 
C18:1 3 0.190 0.180 0.907 
C18:2 n-6 LA 3 0.059 3.458 0.031 
C18:3 n-6 3 0.004 1.471 0.245 
C18:3 n-3 ALA 3 0.001 1.828 0.166 
C18:4 n-3 3 <0.001 2.176 0.114 
C20:0 3 0.007 0.895 0.456 
C20:1 3 0.269 0.632 0.600 
C20:2 n-6 3 0.075 0.990 0.412 
C20:3 n-6* 3 0.072 17.76 <0.001 
 C20:4 n-6 AA* 3 4.233 9.695 <0.001 
C20:3 n-3 3 0.003 0.994 0.378 
C20:4 n-3 3 0.003 1.102 0.365 
C20:5 n-3 EPA* 3 0.069 42.85 <0.001 
C22:0 3 0.006 1.53 0.452 
C22:1 3 0.008 0.533 0.663 
C22:2 n-6 3 0.001 0.892 0.457 
C22:4 n-6* 3 0.948 41.82 <0.001 
C22:5 n-6* 3 0.330 91.82 <0.001 
C22:5 n-3* 3 0.487 170.5 <0.001 
C22:6 n-3 DHA* 3 4.587 7.427 <0.001 
C24:0 3 0.010 0.233 0.872 
C24:1 3 0.259 0.620 0.608 
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Table 6: Mean brain lipid composition (%) +/- one standard deviation of each fatty acid 
for each dietary group (EPA, DHA, ALA, CTRL). *indicates a significant at p<0.05, ** 
indicates a significance at p<0.01, and *** indicates a difference at p<0.005, as compared 
to palm oil control groups from Tukey Test analysis. CTRL = palm oil control, EPA = 
eicosapentaenoic acid, DHA = docosahexaenoic acid, ALA = alpha-linolenic acid. 
 EPA DHA ALA CTRL 
C14:0 0.22 +/- 0.02 0.23 +/- 0.05 0.21 +/- 0.02 0.21 +/- 0.02 
C14:1 0.05 +/- 0.03 0.19 +/- 0.34 0.04 +/- 0.03 0.04 +/- 0.02 
C15:0 0.12 +/- 0.09 0.11 +/- 0.05 0.13 +/- 0.12 0.13 +/- 0.07 
C16:0 22.41 +/- 1.01 22.46 +/- 1.03 22.6 +/- 1.05 22.24 +/- 1.17 
C16:1 0.52 +/- 0.08 0.55 +/- 0.06 0.54 +/- 0.08 0.5 +/- 0.03 
C18:0 19.36 +/- 0.55 19.28 +/- 0.4 19.47 +/- 0.21 19.09 +/- 0.51 
C18:1 24.3 +/- 1.42 24.21 +/- 0.37 23.9 +/- 0.79 24.13 +/- 1.16 
C18:2n6 0.82 +/- 0.22 0.84 +/- 0.07 0.79 +/- 0.06 0.65 +/- 0.09 
C18:3n6 0.02 +/- 0.03 0 +/- 0 0 +/- 0 0.05 +/- 0.11 
C18:3n3 0.03 +/- 0.04 0 +/- 0.01 0.01 +/- 0.02 0.02 +/- 0.03 
C18:4n3 0.01 +/- 0.02 0 +/- 0 0 +/- 0 0 +/- 0 
C20:0 0.53 +/- 0.07 0.51 +/- 0.08 0.51 +/- 0.08 0.58 +/- 0.11 
C20:1 3.37 +/- 0.36 3.35 +/- 0.4 3.32 +/- 0.6 3.72 +/- 1.02 
C20:2n6 0.71 +/- 0.48 0.53 +/- 0.2 0.51 +/- 0.09 0.5 +/- 0.05 
C20:3n6* 0.54 +/- 0.06* 0.62 +/- 0.05* 0.52 +/- 0.02* 0.39 +/- 0.09 
C20:4n6 * 8.22 +/- 0.89* 8.19 +/- 0.49* 9.34 +/- 0.54 9.61 +/- 0.62 
C20:3n3 0 +/- 0 0 +/- 0 0 +/- 0 0 +/- 0 
C20:4n3 0.04 +/- 0.1 0 +/- 0 0 +/- 0 0 +/- 0.01 
C20:5n3 * 0.2 +/- 0.06* 0.09 +/- 0.05* 0.01 +/- 0.02 0 +/- 0 
C22:0 0 +/- 0 0 +/- 0 0 +/- 0 0 +/- 0 
C22:1 0.3 +/- 0.1 0.31 +/- 0.13 0.28 +/- 0.15 0.36 +/- 0.11 
C22:2n6 0.02 +/- 0.02 0 +/- 0.01 0.02 +/- 0.03 0.02 +/- 0.03 
C22:4n6* 1.98 +/- 0.18** 1.88 +/- 0.16** 2.3 +/- 0.13* 2.64 +/- 0.11 
C22:5n6* 0.12 +/- 0.08* 0.02 +/- 0.05** 0.11 +/- 0.06* 0.48 +/- 0.05 
C22:5n3* 0.71 +/- 0.09** 0.35 +/- 0.02* 0.31 +/- 0.04* 0.12 +/- 0.03 
C22:6n3* 12.64 +/- 0.98 13.71 +/- 0.61* 12.76 +/- 0.49 11.86 +/- 0.89 
C24:0 0.89 +/- 0.21 0.96 +/- 0.25 0.9 +/- 0.12 0.95 +/- 0.22 
C24:1 1.86 +/- 0.92 1.6 +/- 0.62 1.4 +/- 0.42 1.71 +/- 0.44 
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Figure 14: The effect of dietary omega-3 polyunsaturated fatty acid (PUFA) 
supplementation on total omega-3 PUFA concentrations in liver. Error bars indicate 
standard deviation. Average values are expressed as a percentage of total lipids. * 
indicates a statistically significant difference was found by ANOVA and Tukey Tests 
(p<0.05) from palm oil control group. ** indicates a statistically significant difference at 
p<0.01. EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid, ALA = alpha-
linolenic acid, CTRL = palm oil control. 
 
 
Figure 15: The effect of dietary omega-3 polyunsaturated fatty acid (PUFA) 
supplementation on the omega-3/omega-6 PUFA ratio in liver. Error bars indicate 
standard deviation. Average values are expressed as a percentage of total lipids. * 
indicates a statistically significant difference was found by ANOVA and Tukey Tests 
(p<0.05) from palm oil control group. ** indicates a statistically significant difference at 
p<0.01. EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid, ALA = alpha-
linolenic acid, CTRL = palm oil control. 
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Table 10: ANOVA results testing for significant differences in liver headspace aldehyde 
concentrations at room temperature (22°C). F-values are used to find significant 
differences between dietary groups. df of 3 indicates that there were 4 dietary groups 
analyzed (CTRL, EPA, DHA, and ALA). No significant differences were found (p>0.05). 
RT-22C  LIVER    
Aldehyde  df  F  P  
Propanal  3  0.4344  0.7302  
Hexanal  3  0.2597  0.8537  
Butanal  3  0.2602  0.8534  
Pentanal  3  1.8422  0.1643  
Heptanal  3  0.5081  0.6801  
Octanal  3  1.2197  0.3224  
Formaldehyde  3  0.0582  0.9811  
Acetaldehyde  3  0.8078  0.5010  
 
Table 11: ANOVA results testing for significant differences in brain headspace aldehyde 
concentrations at 40°C. F-values are used to find significant differences between dietary 
groups. df of 3 indicates that there were 4 dietary groups analyzed (CTRL, EPA, DHA, 
and ALA). *indicates a significant difference was found between groups (p<0.05).  
40C  LIVER    
Aldehyde  df  F  P  
Propanal  3  0.0322  0.9920  
Hexanal  3  0.1164  0.9497  
Butanal*  3  3.3991  0.0326  
Pentanal  3  0.4184  0.7413  
Heptanal  3  0.3290  0.8044  
Octanal  3  1.1207  0.3588  
Formaldehyde  3  0.2618  0.8523  
Acetaldehyde  3  0.7570  0.5284  
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Figure 28: The metabolism of EPA to 3-series prostanoids. EPA follows a similar 
pathway to that of AA, using the same enzymes for conversion into its eicosanoids (Rose 
and Connolly, 1990).  
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